<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Vaccines</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Vaccines</journal-id><journal-id journal-id-type="pmc-domain-id">3297</journal-id><journal-id journal-id-type="pmc-domain">npjvac</journal-id><journal-title-group><journal-title>NPJ Vaccines</journal-title></journal-title-group><issn pub-type="epub">2059-0105</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11379892</article-id><article-id pub-id-type="pmcid-ver">PMC11379892.1</article-id><article-id pub-id-type="pmcaid">11379892</article-id><article-id pub-id-type="pmcaiid">11379892</article-id><article-id pub-id-type="pmid">39242587</article-id><article-id pub-id-type="doi">10.1038/s41541-024-00958-1</article-id><article-id pub-id-type="publisher-id">958</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Progress on the research and development of plague vaccines with a call to action</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0322-5972</contrib-id><name name-style="western"><surname>Williamson</surname><given-names initials="ED">E. Diane</given-names></name><address><email>LHPPTN@dstl.gov.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kilgore</surname><given-names initials="PB">Paul B.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hendrix</surname><given-names initials="EK">Emily K.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0002-8091-0604</contrib-id><name name-style="western"><surname>Neil</surname><given-names initials="BH">Blake H.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sha</surname><given-names initials="J">Jian</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Chopra</surname><given-names initials="AK">Ashok K.</given-names></name><address><email>achopra@utmb.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04jswqb94</institution-id><institution-id institution-id-type="GRID">grid.417845.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0376 1104</institution-id><institution>Defence Science and Technology Laboratory, </institution><institution>Porton Down, </institution></institution-wrap>Salisbury, SP4 0JQ UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.176731.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1547 9964</institution-id><institution>Department of Microbiology and Immunology, </institution><institution>UTMB, </institution></institution-wrap>Galveston, TX 77555 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.176731.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1547 9964</institution-id><institution>Sealy Institute for Vaccine Sciences, </institution><institution>UTMB, </institution></institution-wrap>Galveston, TX 77555 USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.176731.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1547 9964</institution-id><institution>Institute for Human Infections and Immunity, </institution><institution>UTMB, </institution></institution-wrap>Galveston, TX 77555 USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.176731.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1547 9964</institution-id><institution>Center for Biodefense and Emerging Infectious Diseases, </institution><institution>UTMB, </institution></institution-wrap>Galveston, TX 77555 USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.176731.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1547 9964</institution-id><institution>Galveston National Laboratory, </institution><institution>UTMB, </institution></institution-wrap>Galveston, TX 77555 USA </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">452201</issue-id><elocation-id>162</elocation-id><history><date date-type="received"><day>23</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>07</day><month>09</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-08 15:25:16.857"><day>08</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; Crown 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41541_2024_Article_958.pdf"/><abstract id="Abs1"><p id="Par1">There is a compelling demand for approved plague vaccines due to the endemicity of <italic toggle="yes">Yersinia pestis</italic> and its potential for pandemic spread. Whilst substantial progress has been made, we recommend that the global funding and health security systems should work urgently to translate some of the efficacious vaccines reviewed herein to expedite clinical development and to prevent future disastrous plague outbreaks, particularly caused by antimicrobial resistant <italic toggle="yes">Y. pestis</italic> strains.</p><p id="Par2">Content includes material subject to Crown Copyright &#169; 2024.This is an open access article under the Open Government License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/">http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/</ext-link>).</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Bacterial infection</kwd><kwd>Bacterial infection</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Main text</title><sec id="Sec2"><title>Epidemiology of plague</title><p id="Par3">Plague, caused by the gram-negative bacterium <italic toggle="yes">Yersinia pestis</italic>, is notorious for its involvement in three of the seven deadliest pandemics recorded in global history, including the recent COVID-19 pandemic. The three historic plague pandemics, the most infamous of which was the Black Death of the Middle Ages, collectively caused an estimated 200 million deaths<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. Unfortunately, plague is still an endemic disease in parts of the world, with outbreaks being reported to the WHO from over 33 countries including Madagascar, Democratic Republic of the Congo (DRC), India, China, Peru, and occasionally, the south-western USA<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. In these regions, disease is maintained by the existence of infected animal (mostly rodent) reservoirs of <italic toggle="yes">Y. pestis</italic><sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par4">Transmission to humans is predominantly promoted by flea bite; those fleas having fed on infected rodents (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). However, <italic toggle="yes">Y. pestis</italic> is an obligate parasite and even if the rat population is reduced, the organism can infect mice, prairie dogs, rabbits, and members of the cat family, including the domestic cat<sup><xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref></sup>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Flea-vectored transmission of plague.</title><p>The figure depicts various routes for the flea-vectored transmission of plague to man. The figure is reproduced from Williamson and Westlake (2019)<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> with permission (License 5753521304382, Oxford University Press).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e301" position="float" orientation="portrait" xlink:href="41541_2024_958_Fig1_HTML.jpg"/></fig></p><p id="Par5">Infection through flea bite causes bubonic plague, which if undiagnosed, can develop into a septicemic infection or secondary pneumonic plague. Pneumonic plague is highly contagious requiring prompt antibiotic therapy for survival, as the mortality rate approaches 100% if untreated<sup><xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref></sup>. In pneumonic plague, <italic toggle="yes">Y. pestis</italic> can be transmitted to healthy individuals who are in close contact by respiratory droplets, establishing further cases of primary pneumonic plague, leading to disease outbreaks which may transform into epidemics and pandemics<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>.</p><p id="Par6">With this epidemiology, poor living conditions augment the endemicity of plague, which requires close contact with a rodent population. However, in endemic regions such as Madagascar, the lack of an approved vaccine means that outbreaks have to be controlled by antibiotic therapy, administered to the patients and those in immediate contact with the infected individuals. Whilst timely antibiotic therapy is effective in treating the infection, case fatality rates still reached up to 8.6% during the 2017 Madagascar outbreak despite aggressive antibiotic therapy<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Additionally, there is a demonstrable risk of the development of antibiotic resistance. Indeed, antimicrobial resistant (AMR) <italic toggle="yes">Y. pestis</italic> strains have been identified in Peru and Madagascar<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. Therefore, there is a clear need for a safe, effective, and licensed vaccine for use in endemic regions to control or prevent infection, as well as to protect military and civilians at large from potential biothreat attacks.</p></sec><sec id="Sec3"><title>Emergence of <italic toggle="yes">Yersinia pestis</italic> as a dangerous pathogen</title><p id="Par7"><italic toggle="yes">Y. pestis</italic> has evolved from the relatively mild gastrointestinal <italic toggle="yes">Y. pseudotuberculosis</italic> (notably serotype 1b) between 1500 and 20,000 years ago<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, although archaeological evidence has suggested that the plague-causing bacterium existed long before previous estimates<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p><p id="Par8">The evolution of <italic toggle="yes">Y. pestis</italic> has resulted in the inactivation of genes required for an enteric lifestyle and by the acquisition of plasmids encoding new virulence factor-encoding genes<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. In common with other pathogenic yersiniae (<italic toggle="yes">e.g., Y. pseudotuberculosis</italic> and <italic toggle="yes">Y. enterocolitica</italic>), <italic toggle="yes">Y. pestis</italic> possesses a 70-kilobase (kb) virulence plasmid designated as pYV/pCD1 that carries a Type III secretion system (TTSS) operon<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. However, <italic toggle="yes">Y. pestis</italic> has acquired two additional unique plasmids, including a 9.5-kb pPCP1/pPla/pPst encoding a bacterial surface-bound protease (plasminogen activator, Pla), which has potent fibrinolytic activity<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. In addition, this plasmid possesses pesticin and coagulase encoding genes which enable bacterial transmission from the flea<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. The other 100&#8211;110&#8201;kb pFra/pMT1 plasmid<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> codes for two important proteins, Fraction 1 (F1) antigen and a phospholipase D known as murine toxin. The F1 antigen forms a polymeric anti-phagocytic capsule around the bacteria<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> whilst murine toxin has a role in preserving <italic toggle="yes">Y. pestis</italic> in the flea gut<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. During its evolution from enteric to flea-vectored pathogen, <italic toggle="yes">Y. pestis</italic> has lost intestinal adhesin and invasin genes, but has retained the heme locus and possesses a number of chromosomal-encoded genes such as the <italic toggle="yes">ph6/psa</italic> fimbrial and attachment-invasion locus (<italic toggle="yes">ail</italic>) which promote colonization to the host cells<sup><xref ref-type="bibr" rid="CR19">19</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref></sup>.</p></sec><sec id="Sec4"><title>Evasion of host responses</title><p id="Par9">In the process of acquiring a new mechanism of infection, <italic toggle="yes">Y</italic>. <italic toggle="yes">pestis</italic> has also activated genes which enable the pathogen to evade the defenses of its successive hosts. In purified or recombinant forms, some of these encoded gene products have provided vaccine targets and are therefore summarized here.</p><p id="Par10"><italic toggle="yes">Y. pestis</italic> can survive and grow in the flea&#8217;s (most notably the rat flea <italic toggle="yes">Xenopsylla cheopis</italic>) foregut, leading to &#8216;blockage&#8217; of the flea. The proper functioning of the bacterial hemin storage system is thought to play an important role in the formation of this blockage<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, which during the flea bite, results in the regurgitation of a dense bolus of bacteria<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> into a new host. <italic toggle="yes">Y. pestis</italic> expresses other genes in the flea gut such as a &#8216;murine&#8217; toxin with phospholipase D activity<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> and a lipopolysaccharide (LPS) core modification locus, which together are required for biofilm formation and blockage of the flea<sup><xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref></sup>. However, transcriptional analysis of <italic toggle="yes">Y. pestis</italic> in the flea gut has identified a wide range of additional genes, such as insecticidal-like toxin genes, which are differentially regulated such that bacteria regurgitated into a new host have increased resistance to innate immune effectors<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>.</p><p id="Par11">Upon infection of a new mammalian host, the plague bacilli are vulnerable to phagocytosis by polymorphonuclear leukocytes (PMNs or neutrophils) and/or monocytes. The bacteria may be killed within PMNs, but can persist within monocytes and express various virulence determinants, allowing <italic toggle="yes">Y. pestis</italic> growth and eventual release from the monocytes<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. The fibrillar adhesin pH6 antigen is induced by low phagosomal pH (4.5)<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> and promotes bacterial adhesion to host cells, thereby enhancing resistance to phagocytosis<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Secretion of the F1 antigen with capsule formation is triggered by a temperature shift from 28&#8201;&#176;C in the flea to 37&#8201;&#176;C in humans or other mammals. The F1 capsule also plays a key role in avoiding phagocytosis<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. However, non-capsulated <italic toggle="yes">Y. pestis</italic> retains its full capability to cause pneumonic infection in animals, while having reduced virulence during bubonic infection<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>.</p><p id="Par12">The dominant anti-host effects are due to a temperature shift induction of the TTSS carried on the virulence plasmid pYV/pCD1. TTSS effectors, historically called <italic toggle="yes">Yersinia</italic> outer membrane proteins (Yops), have cytotoxic and phagocyte regulatory effects, are secreted through an injectosome after <italic toggle="yes">Y. pestis</italic> makes contact with the host cell, and are delivered into target cells<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. The function of many of the Yops has been delineated for this well-characterized secretion system, and serves as a paradigm for other bacterial TTSS&#8217;s<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. For example, the YopE protein is a cytotoxin and the YopH protein is a tyrosine phosphatase with anti-phagocytic activity<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. The V (or Low calcium response V, LcrV) antigen plays a pivotal role by orchestrating intracellular Yop low calcium response protein G (LcrG) elaboration of the injectosome and then itself being delivered through this needle-like structure to be assembled as a pentamer at the tip<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Additionally, V antigen secreted from <italic toggle="yes">Y. pestis</italic> exerts a local immunomodulatory effect in the host by down-regulating the production of interferon-&#947; (IFN&#947;) and tumor necrosis factor-&#945; (TNF&#945;)<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>.</p><p id="Par13">Plasminogen activator (Pla) is another major virulence factor in <italic toggle="yes">Y. pestis</italic>. Pla is an outer membrane-located protease, which breaks down the physical barriers of connective tissue in the host, thus promoting the systemic dissemination of the bolus of <italic toggle="yes">Y. pestis</italic> injected by the flea. The requirement for Pla has driven the selection in <italic toggle="yes">Y. pestis</italic> of the &#8220;rough&#8221; phenotype of LPS, which lacks an O antigen<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>, a rare phenomenon amongst gram-negative bacteria which has possibly resulted from the bacterium&#8217;s transmission through the flea, but which is necessary for Pla to be functional<sup><xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. Inactivation of the O-antigens on <italic toggle="yes">Y. pestis</italic> LPS exposes the LPS core, so that <italic toggle="yes">Y. pestis</italic> can interact with C-type lectin receptors on host macrophages, promoting its uptake, and thus accelerating bacterial dissemination in the host<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. Our study has also shown that the &#916;<italic toggle="yes">pla</italic> mutant is unable to survive efficiently in murine and human macrophages, unlike the wild-type <italic toggle="yes">Y. pestis</italic><sup><xref ref-type="bibr" rid="CR38">38</xref></sup>.</p><p id="Par14">The bacteria disseminate from the site of primary infection into draining regional lymph nodes. Within the lymph node, further growth of the bacteria accompanied by a massive inflammatory reaction leads to lymphadenopathy and the formation of buboes, typically in the groin or axillae. In the bubo, bacteria are predominantly extracellular, mainly due to the TTSS which is highly expressed in the lymph node<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. An ability to proliferate in the bubo<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> is enabled by the efficient and abundant iron acquisition systems possessed by <italic toggle="yes">Y. pestis</italic><sup><xref ref-type="bibr" rid="CR41">41</xref></sup>.</p><p id="Par15">Eventually, the bacteria are disseminated by the lymphatic system, gain access to the blood stream, and colonize pulmonary tissues, which may lead to development of the pneumonic form of the disease. When left untreated, pneumonic plague induces an overwhelming septicemia which triggers septic shock in the host. However, the precise mechanisms that lead to the death of the host have not been identified but involve multi-organ failure, during which the systemic induction of nitric oxide synthase may contribute, as seen with other gram-negative septicemias<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>.</p><p id="Par16">Whilst pigmentation (<italic toggle="yes">pgm</italic>)-negative strains of <italic toggle="yes">Y. pestis</italic> are usually avirulent and attenuated, the risk of reversion to virulence was highlighted by the fatal case of a laboratory worker who was unknowingly suffering from hemochromatosis and was exposed to the attenuated <italic toggle="yes">pgm</italic><sup>-</sup>
<italic toggle="yes">Y. pestis</italic> laboratory strain KIM. This individual developed plague and died, presumably due to his hemochromatosis-induced iron overload condition providing the infecting KIM strain, attenuated through defects in its iron acquisition ability, with sufficient iron to render it virulent<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>.</p></sec><sec id="Sec5"><title>Early vaccines</title><p id="Par17">The early use of an inactivated whole cell vaccine for plague by Haffkine between 1897 and 1935 successfully curtailed plague outbreaks in India. This was the first demonstration that components of <italic toggle="yes">Y. pestis</italic>, even when inactivated, could be immunogenic. Haffkine&#8217;s heat-killed whole cell (KWC) vaccine was administered to the human population in an estimated 24 million doses<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Early generation plague vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Vaccine</th><th colspan="1" rowspan="1">Type</th><th colspan="1" rowspan="1">Doses</th><th colspan="1" rowspan="1">Route</th><th colspan="1" rowspan="1">Species tested</th><th colspan="1" rowspan="1">Protection</th><th colspan="1" rowspan="1">Type of Immune Response</th><th colspan="1" rowspan="1">Shortcomings</th><th colspan="1" rowspan="1">Years studied (Ref)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Haffkine vaccine</td><td colspan="1" rowspan="1">Heat-killed</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">s.c.</td><td colspan="1" rowspan="1">rabbits</td><td colspan="1" rowspan="1">Bubonic only</td><td colspan="1" rowspan="1">Likely Ab only</td><td colspan="1" rowspan="1">Severely reactogenic</td><td colspan="1" rowspan="1">1897&#8211;1935<sup><xref ref-type="bibr" rid="CR44">44</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Plague vaccine (USP) Or CSL vaccine</td><td colspan="1" rowspan="1"><p>Formalin-inactivated</p><p>Heat-inactivated</p></td><td colspan="1" rowspan="1"><p>3+</p><p>3</p></td><td colspan="1" rowspan="1"><p>i.m.</p><p>i.m.</p></td><td colspan="1" rowspan="1"><p>Mice</p><p>mice</p></td><td colspan="1" rowspan="1">Bubonic only</td><td colspan="1" rowspan="1">Ab</td><td colspan="1" rowspan="1">Frequent boosters, reactogenic</td><td colspan="1" rowspan="1">1939&#8211;1999<sup><xref ref-type="bibr" rid="CR45">45</xref>&#8211;<xref ref-type="bibr" rid="CR53">53</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Live plague vaccine (EV76, EVNIIEG)</td><td colspan="1" rowspan="1">Live-attenuated</td><td colspan="1" rowspan="1">1+</td><td colspan="1" rowspan="1">Various $</td><td colspan="1" rowspan="1">Mice, Rats, Guinea Pigs, NHP&#8217;s*</td><td colspan="1" rowspan="1">Both bubonic and pneumonic</td><td colspan="1" rowspan="1">Ab and CMI</td><td colspan="1" rowspan="1">Frequent boosters, Reactogenic, Virulent during iron overload</td><td colspan="1" rowspan="1">1936&#8211;present<sup><xref ref-type="bibr" rid="CR54">54</xref>&#8211;<xref ref-type="bibr" rid="CR57">57</xref></sup></td></tr></tbody></table><table-wrap-foot><p>Dollar sign indicates various routes include skin scarification, intradermal, sub-cutaneous (s.c.), oral (p.o) and inhalational. Asterisk indicates live plague vaccine can cause disease in African Green monkeys (AGMs). In humans, EV76 is recommended to be administered once a year. It is used in Former States of Soviet Union and regions where plague is endemic but is not approved in USA/Europe; antibodies to F1, LcrV and YscF have been detected in vaccinated humans. Commonwealth Serum Laboratories (CSL) in Australia produced heat-killed vaccine, administered in 3 doses in humans. <italic toggle="yes">Ab</italic> Antibody, <italic toggle="yes">CMI</italic> Cell-mediated immunity, <italic toggle="yes">GP</italic> guinea pig, <italic toggle="yes">NHP</italic> non-human primate, <italic toggle="yes">s.c.</italic> sub-cutaneous, <italic toggle="yes">i.m.</italic> intra-muscular.</p></table-wrap-foot></table-wrap></p><p id="Par18">During the 1990s, there were several commercial suppliers of the KWC vaccine against plague. Subsequently, plague vaccine USP (United States Pharmacopeia; 1939&#8211;1999), containing formaldehyde-killed bacteria, was manufactured by Cutter Laboratories, USA. In 1994, the manufacturing was transferred to Greer Laboratories Inc., USA. In 1999, the production of this vaccine was discontinued largely because of severe side effects and its protection against bubonic but limited efficacy against pneumonic plague<sup><xref ref-type="bibr" rid="CR45">45</xref>&#8211;<xref ref-type="bibr" rid="CR52">52</xref></sup>. An alternative heat-killed (KWC) vaccine was also manufactured by the Commonwealth Serum Laboratories (CSL, Australia)<sup><xref ref-type="bibr" rid="CR53">53</xref></sup> and until November 2005, was licensed for clinical use in Australia. Additionally, a <italic toggle="yes">Y. pestis</italic> isolate (EV76-NIIEG <italic toggle="yes">Y. pestis</italic>)<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>, which is attenuated due to deletion of the pigmentation locus (<italic toggle="yes">pgm</italic>), has been used as a vaccine for many years and is licensed for use in China and Russia specifically<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> where plague is endemic. The vaccine can be administered by various routes; however, the vaccine is fully virulent under iron-overload conditions, <italic toggle="yes">i.e</italic>., in individuals with hemochromatosis<sup><xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup> (Table <xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec6"><title>Virulence factors as vaccine antigens</title><p id="Par19">The seminal observation in 1956 by Bacon and Burrows that <italic toggle="yes">Pasteurella pestis</italic> (now <italic toggle="yes">Y. pestis</italic>) could be anti-phagocytic in the absence of capsule, led to the identification of a new virulence antigen, which they named the V antigen<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. This paved the way for subsequent research to the present day on the immunogenic and protective potential of this and other virulence factors of <italic toggle="yes">Y. pestis</italic><sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup>. Building on the observation that the F1 antigen-containing Cutter KWC vaccine needed the addition of a recombinant V (rV) antigen to fully protect mice against pneumonic plague<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>, Williamson, et al. demonstrated the synergistic effect of F1 and V in combination. Whilst vaccines lacking the V antigen may protect against bubonic plague, several groups showed that the inclusion of the V antigen was an essential requirement for protection against pneumonic plague<sup><xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR62">62</xref></sup>.</p><p id="Par20">Much work has been carried out to determine the protective potential of other antigens derived from <italic toggle="yes">Y. pestis</italic> in native or recombinant form in addition to F1 and V, such as Pla, a protein constituent of the injectisome known as <italic toggle="yes">Yersinia</italic> secretory factor F (YscF), and a range of other Yops, and their various combinations<sup><xref ref-type="bibr" rid="CR63">63</xref>&#8211;<xref ref-type="bibr" rid="CR67">67</xref></sup>. Whilst some of these imparted partial protective efficacy and are useful adjuncts in some vaccine formulations (see below), to date F1 and V remain the key proteins which individually have protective efficacy, but which in combination, are consistently synergistic and, therefore, form the core building blocks of most vaccine approaches.</p></sec><sec id="Sec7"><title>Vaccines for plague</title><p id="Par21">Currently, there are more than 21 candidate vaccines in the preclinical phase<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Below, we have reviewed the pre-clinical candidates (Tables <xref rid="Tab1" ref-type="table">1</xref>&#8211;<xref rid="Tab5" ref-type="table">5</xref>) and subsequently those that are in early clinical development with a timeline (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). The pre-clinical candidates can be broadly categorised as subunit, live attenuated, vectored (bacterial or viral), DNA, or messenger RNA (mRNA).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>New subunit plague vaccines and adjuvants</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Vaccine</th><th colspan="1" rowspan="1">Doses</th><th colspan="1" rowspan="1">Adjuvant</th><th colspan="1" rowspan="1">Route</th><th colspan="1" rowspan="1">Species tested</th><th colspan="1" rowspan="1">Efficacy*</th><th colspan="1" rowspan="1">Immune response type</th><th colspan="1" rowspan="1">Years studied (Ref)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">rF1-V</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Alum</td><td colspan="1" rowspan="1">s.c.</td><td colspan="1" rowspan="1">Mice. NHP</td><td colspan="1" rowspan="1">Pneumonic</td><td colspan="1" rowspan="1">Ab</td><td colspan="1" rowspan="1">1998&#8211;present<sup><xref ref-type="bibr" rid="CR60">60</xref></sup><sup>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR85">85</xref></sup></td></tr><tr><td colspan="1" rowspan="1">rF1&#8201;+&#8201;rV</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Alum</td><td colspan="1" rowspan="1">i.m.</td><td colspan="1" rowspan="1">Mice, GP, NHP</td><td colspan="1" rowspan="1">Pneumonic</td><td colspan="1" rowspan="1">Ab</td><td colspan="1" rowspan="1">1995&#8211;2011<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR71">71</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><p>Calcium phosphate</p><p>Protein-coated microcrystals (PCMC) F1V</p></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Alum</td><td colspan="1" rowspan="1">s.c.</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Pneumonic</td><td colspan="1" rowspan="1">Ab</td><td colspan="1" rowspan="1">2018&#8211;2022<sup><xref ref-type="bibr" rid="CR82">82</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Flagellin F1-V</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Flagellin</td><td colspan="1" rowspan="1">i.m.</td><td colspan="1" rowspan="1"><p>Mice</p><p>NHP <sup>$</sup></p></td><td colspan="1" rowspan="1">Pneumonic</td><td colspan="1" rowspan="1">Ab</td><td colspan="1" rowspan="1">2006&#8211;2020<sup><xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR75">75</xref>,<xref ref-type="bibr" rid="CR124">124</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Protollin F1-V**</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Protollin</td><td colspan="1" rowspan="1">i.n.</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Pneumonic</td><td colspan="1" rowspan="1">Ab</td><td colspan="1" rowspan="1">2006<sup><xref ref-type="bibr" rid="CR73">73</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><p>Single dose F1-V</p><p>Polyanhydride nanoparticles coupled with cyclic dinucleotides</p></td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">STING (stimulator of interferon genes) agonist</td><td colspan="1" rowspan="1">i.n.</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Pneumonic</td><td colspan="1" rowspan="1">Ab and cell-mediated (CMI)</td><td colspan="1" rowspan="1">2019<sup><xref ref-type="bibr" rid="CR76">76</xref></sup></td></tr><tr><td colspan="1" rowspan="1">rV10</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">alum</td><td colspan="1" rowspan="1">i.m.</td><td colspan="1" rowspan="1">Mice, GP, NHP</td><td colspan="1" rowspan="1">Pneumonic</td><td colspan="1" rowspan="1">Ab</td><td colspan="1" rowspan="1">2005&#8211;2011<sup><xref ref-type="bibr" rid="CR71">71</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Peptidoglycan-free OMV (Bacterial ghosts)-phage lytic system</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">self</td><td colspan="1" rowspan="1">s.c.</td><td colspan="1" rowspan="1"><p>Mice</p><p>GP</p></td><td colspan="1" rowspan="1">Bubonic</td><td colspan="1" rowspan="1">Ab and CMI</td><td colspan="1" rowspan="1">2021<sup><xref ref-type="bibr" rid="CR78">78</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Manganese silicate nanoparticle rF1-V10</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">self</td><td colspan="1" rowspan="1">s.c.</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Pneumonic</td><td colspan="1" rowspan="1">Ab and CMI</td><td colspan="1" rowspan="1">2023<sup><xref ref-type="bibr" rid="CR77">77</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Polymeric F1&#8201;+&#8201;LcrV (ILB1)-R</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">alum</td><td colspan="1" rowspan="1">s.c.</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Pneumonic</td><td colspan="1" rowspan="1">Ab</td><td colspan="1" rowspan="1">2023<sup><xref ref-type="bibr" rid="CR72">72</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Y. pseudotuberculosis</italic>-based LcrV MPLA OMV</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">MPLA (monophosphoryl lipid A)</td><td colspan="1" rowspan="1">i.m.</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Pneumonic</td><td colspan="1" rowspan="1">Ab and CMI</td><td colspan="1" rowspan="1">2020&#8211;2023<sup><xref ref-type="bibr" rid="CR81">81</xref>,<xref ref-type="bibr" rid="CR105">105</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Plague microencapsulated vaccine (licensed in Russia)</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Alum&#8201;+&#8201;self</td><td colspan="1" rowspan="1">s.c.</td><td colspan="1" rowspan="1"><p>Mice</p><p>GP</p><p>NHP</p><p>Humans</p></td><td colspan="1" rowspan="1">Bubonic</td><td colspan="1" rowspan="1">Ab and CMI</td><td colspan="1" rowspan="1">1983&#8211;2018<sup><xref ref-type="bibr" rid="CR86">86</xref></sup></td></tr></tbody></table><table-wrap-foot><p>Asterisk indicates pneumonic infection can be <italic toggle="yes">via</italic> aerosol or intra-nasal. Double asterisk indicates proteosomes are non-covalently coupled to LPS. Dollar sign indicates no challenge data shown. <italic toggle="yes">GP</italic> Guinea pig, <italic toggle="yes">NHP</italic> Non-human primate, <italic toggle="yes">OMV</italic> outer membrane vesicles, <italic toggle="yes">Ab</italic> Antibody, <italic toggle="yes">CMI</italic> Cell-mediated immunity, <italic toggle="yes">s.c.</italic> sub-cutaneous, <italic toggle="yes">i.m.</italic> intra-muscular, <italic toggle="yes">i.n.</italic> intra-nasal.</p></table-wrap-foot></table-wrap><table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>New generation live- attenuated plague vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Vaccine</th><th colspan="1" rowspan="1">Doses</th><th colspan="1" rowspan="1">Mutation</th><th colspan="1" rowspan="1">Route</th><th colspan="1" rowspan="1">Species tested</th><th colspan="1" rowspan="1">Safety shown in immuno-compromised models</th><th colspan="1" rowspan="1">Efficacy</th><th colspan="1" rowspan="1">Type of immune response</th><th colspan="1" rowspan="1">Years studied (Ref)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Y<italic toggle="yes">. pestis</italic> CO92 &#916;LMA*</td><td colspan="1" rowspan="1">1&#8211;2</td><td colspan="1" rowspan="1"><italic toggle="yes">lpp, msbB, ail</italic></td><td colspan="1" rowspan="1">i.n. or i.m.</td><td colspan="1" rowspan="1">Mice, rats</td><td colspan="1" rowspan="1">Rag1 KOO/iron overload**</td><td colspan="1" rowspan="1">pneumonic</td><td colspan="1" rowspan="1">Ab and CMI</td><td colspan="1" rowspan="1">2015<sup><xref ref-type="bibr" rid="CR88">88</xref>&#8211;<xref ref-type="bibr" rid="CR91">91</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Y. pestis</italic> CO92 &#916;LMP</td><td colspan="1" rowspan="1">1&#8211;2</td><td colspan="1" rowspan="1"><italic toggle="yes">lpp, msbB, pla</italic></td><td colspan="1" rowspan="1">i.m.</td><td colspan="1" rowspan="1">Mice, rats</td><td colspan="1" rowspan="1">safe</td><td colspan="1" rowspan="1">pneumonic</td><td colspan="1" rowspan="1">Ab and CMI</td><td colspan="1" rowspan="1">2016<sup><xref ref-type="bibr" rid="CR88">88</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Y. pestis</italic> EV76-B-SHU &#916;pla</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1"><italic toggle="yes">pgm, pla</italic></td><td colspan="1" rowspan="1">i.t. or s.c.</td><td colspan="1" rowspan="1">mice</td><td colspan="1" rowspan="1">Not tested</td><td colspan="1" rowspan="1">pneumonic</td><td colspan="1" rowspan="1">Ab and CMI</td><td colspan="1" rowspan="1">2020<sup><xref ref-type="bibr" rid="CR92">92</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Y. pestis</italic> CO92 &#916;pgm&#916;pPst</td><td colspan="1" rowspan="1">1&#8211;2</td><td colspan="1" rowspan="1"><italic toggle="yes">pPgm, pPst (pla)</italic></td><td colspan="1" rowspan="1">s.c.</td><td colspan="1" rowspan="1">mice</td><td colspan="1" rowspan="1">Not tested</td><td colspan="1" rowspan="1">pneumonic</td><td colspan="1" rowspan="1">Ab and CMI</td><td colspan="1" rowspan="1">2021<sup><xref ref-type="bibr" rid="CR93">93</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Y. pestis</italic> CO92 &#916;yscN</td><td colspan="1" rowspan="1">1&#8211;2</td><td colspan="1" rowspan="1"><italic toggle="yes">yscN</italic></td><td colspan="1" rowspan="1">s.c.</td><td colspan="1" rowspan="1">mice</td><td colspan="1" rowspan="1">Not tested</td><td colspan="1" rowspan="1">Bubonic and pneumonic</td><td colspan="1" rowspan="1">Ab and CMI</td><td colspan="1" rowspan="1">2021<sup><xref ref-type="bibr" rid="CR93">93</xref></sup></td></tr></tbody></table><table-wrap-foot><p>Single asterisk indicates no clinical symptoms observed in cynomolgus macaques or African Green monkeys (unpublished), double asterisk indicates avirulent under iron overload conditions. <italic toggle="yes">Ab</italic> Antibody, <italic toggle="yes">CMI</italic> Cell-mediated immunity, <italic toggle="yes">s.c.</italic> sub-cutaneous, <italic toggle="yes">i.m.</italic> intra-muscular, <italic toggle="yes">i.n.</italic> intra-nasal, <italic toggle="yes">i.t.</italic> intra-tracheal.</p></table-wrap-foot></table-wrap><table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>DNA and bacterial and viral-based, as well as mRNA-based plague vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Vaccine</th><th colspan="1" rowspan="1">Type</th><th colspan="1" rowspan="1">Doses</th><th colspan="1" rowspan="1">Route</th><th colspan="1" rowspan="1">Species tested</th><th colspan="1" rowspan="1">Efficacy</th><th colspan="1" rowspan="1">Immune response</th><th colspan="1" rowspan="1">Years studied (Ref)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">DNA F1-V</td><td colspan="1" rowspan="1">DNA vaccine</td><td colspan="1" rowspan="1">Up to 6</td><td colspan="1" rowspan="1">i.m.</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">pneumonic</td><td colspan="1" rowspan="1">Ab &amp; CMI</td><td colspan="1" rowspan="1">1999&#8211;2012<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR119">119</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Ad5-F1&#8201;+&#8201;Ad5-LcrV</td><td colspan="1" rowspan="1">Adenoviral vector</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">i.m.</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">pneumonic</td><td colspan="1" rowspan="1">both</td><td colspan="1" rowspan="1">2006&#8211;2010<sup><xref ref-type="bibr" rid="CR116">116</xref>,<xref ref-type="bibr" rid="CR118">118</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Ad5-YFV</td><td colspan="1" rowspan="1">Adenoviral vector</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">i.n.</td><td colspan="1" rowspan="1">Mice, NHP</td><td colspan="1" rowspan="1">pneumonic</td><td colspan="1" rowspan="1">both</td><td colspan="1" rowspan="1">2016&#8211;2023<sup><xref ref-type="bibr" rid="CR113">113</xref>,<xref ref-type="bibr" rid="CR114">114</xref></sup></td></tr><tr><td colspan="1" rowspan="1">T4-phage</td><td colspan="1" rowspan="1">Prokaryotic viral vector</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">i.m.</td><td colspan="1" rowspan="1">Mice, rats</td><td colspan="1" rowspan="1">pneumonic</td><td colspan="1" rowspan="1">both</td><td colspan="1" rowspan="1">2013&#8211;2023<sup><xref ref-type="bibr" rid="CR112">112</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">S</italic>. Typhimurium expressing plague antigens</td><td colspan="1" rowspan="1">Bacterial vector</td><td colspan="1" rowspan="1">1&#8211;2</td><td colspan="1" rowspan="1">Mostly p.o.</td><td colspan="1" rowspan="1">mice</td><td colspan="1" rowspan="1">pneumonic</td><td colspan="1" rowspan="1">both</td><td colspan="1" rowspan="1">1996&#8211;2016<sup><xref ref-type="bibr" rid="CR107">107</xref>&#8211;<xref ref-type="bibr" rid="CR109">109</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">S</italic>. Typhi expressing plague antigens</td><td colspan="1" rowspan="1">Bacterial vector</td><td colspan="1" rowspan="1">1&#8211;3</td><td colspan="1" rowspan="1">i.n.</td><td colspan="1" rowspan="1">mice</td><td colspan="1" rowspan="1">Bubonic, septicaemic</td><td colspan="1" rowspan="1">both</td><td colspan="1" rowspan="1">2004&#8211;2009<sup><xref ref-type="bibr" rid="CR106">106</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Lactiplantibacillus plantorum</italic> expressing lcrV</td><td colspan="1" rowspan="1">Bacterial vector</td><td colspan="1" rowspan="1">3*</td><td colspan="1" rowspan="1">p.o.</td><td colspan="1" rowspan="1">mice</td><td colspan="1" rowspan="1">Not tested</td><td colspan="1" rowspan="1">both</td><td colspan="1" rowspan="1">2011<sup><xref ref-type="bibr" rid="CR45">45</xref></sup></td></tr><tr><td colspan="1" rowspan="1">F1-mRNA-LNP</td><td colspan="1" rowspan="1">mRNA-LNP</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">i.m.</td><td colspan="1" rowspan="1">mice</td><td colspan="1" rowspan="1">bubonic</td><td colspan="1" rowspan="1">both</td><td colspan="1" rowspan="1">2023<sup><xref ref-type="bibr" rid="CR120">120</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Y. pseudotuberculosis</italic> producing F1</td><td colspan="1" rowspan="1">Bacterial vector</td><td colspan="1" rowspan="1">1+</td><td colspan="1" rowspan="1">s.c or p.o.</td><td colspan="1" rowspan="1">mice</td><td colspan="1" rowspan="1">Bubonic, pneumonic</td><td colspan="1" rowspan="1">both</td><td colspan="1" rowspan="1">2008&#8211;2020<sup><xref ref-type="bibr" rid="CR101">101</xref>&#8211;<xref ref-type="bibr" rid="CR104">104</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Self-amplifying mRNA(F1&#8201;+&#8201;lcrV)</td><td colspan="1" rowspan="1">mRNA-LNP</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">i.m.</td><td colspan="1" rowspan="1">mice</td><td colspan="1" rowspan="1">bubonic</td><td colspan="1" rowspan="1">both</td><td colspan="1" rowspan="1">2023<sup><xref ref-type="bibr" rid="CR121">121</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">F. tularensis</italic>&#916;<italic toggle="yes">capB</italic>&#8201;+&#8201;F1-LcrV/PA</td><td colspan="1" rowspan="1">Bacterial vector</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">i.m., i.n.</td><td colspan="1" rowspan="1">mice</td><td colspan="1" rowspan="1">Respiratory infection</td><td colspan="1" rowspan="1">both</td><td colspan="1" rowspan="1">2018<sup><xref ref-type="bibr" rid="CR111">111</xref></sup></td></tr></tbody></table><table-wrap-foot><p>Asterisk indicates that each dose consisted of 2x daily administrations for 3&#8211;4 days. <italic toggle="yes">Ab</italic> Antibody, <italic toggle="yes">CMI</italic> Cell-mediated immunity, <italic toggle="yes">s.c</italic>. sub-cutaneous, <italic toggle="yes">i.m.</italic> intra-muscular, <italic toggle="yes">i.n.</italic> intra-nasal, <italic toggle="yes">p.o.</italic> oral.</p></table-wrap-foot></table-wrap><table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Plague vaccines tested in NHP&#8217;s or heterologous vaccination strategy</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Vaccine</th><th colspan="1" rowspan="1">Type</th><th colspan="1" rowspan="1">Adjuvant</th><th colspan="1" rowspan="1">Doses</th><th colspan="1" rowspan="1">Route</th><th colspan="1" rowspan="1">Cyno macaque efficacy</th><th colspan="1" rowspan="1">African Green monkey efficacy</th><th colspan="1" rowspan="1">Type of immune response</th><th colspan="1" rowspan="1">Years studied (Ref)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">rF1-V</td><td colspan="1" rowspan="1">Subunit</td><td colspan="1" rowspan="1">alum</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">s.c.</td><td colspan="1" rowspan="1">80%</td><td colspan="1" rowspan="1">20%</td><td colspan="1" rowspan="1">Ab</td><td colspan="1" rowspan="1">2007&#8211;2018<sup><xref ref-type="bibr" rid="CR51">51</xref></sup></td></tr><tr><td colspan="1" rowspan="1">LicKM-LcrV-F1</td><td colspan="1" rowspan="1">Subunit</td><td colspan="1" rowspan="1">LickM&#8201;+&#8201;alum</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">s.c.</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">Not tested</td><td colspan="1" rowspan="1">Ab</td><td colspan="1" rowspan="1">2007&#8211;2009<sup><xref ref-type="bibr" rid="CR130">130</xref></sup></td></tr><tr><td colspan="1" rowspan="1">rF1&#8201;+&#8201;rV</td><td colspan="1" rowspan="1">Subunit</td><td colspan="1" rowspan="1">alum</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">i.m.</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">Not tested</td><td colspan="1" rowspan="1">Ab</td><td colspan="1" rowspan="1">2011<sup><xref ref-type="bibr" rid="CR68">68</xref></sup></td></tr><tr><td colspan="1" rowspan="1">rV10</td><td colspan="1" rowspan="1">Subunit</td><td colspan="1" rowspan="1">alum</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">i.m.</td><td colspan="1" rowspan="1">100%*</td><td colspan="1" rowspan="1">33%</td><td colspan="1" rowspan="1">Ab</td><td colspan="1" rowspan="1">2011<sup><xref ref-type="bibr" rid="CR71">71</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><p>rAd5-YFV&#8201;+&#8201;rY</p><p>FV</p><p>$</p></td><td colspan="1" rowspan="1">Viral vector with protein boost</td><td colspan="1" rowspan="1">self</td><td colspan="1" rowspan="1">1&#8201;+&#8201;1</td><td colspan="1" rowspan="1">i.n.-i.m.</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">Not tested</td><td colspan="1" rowspan="1">Ab</td><td colspan="1" rowspan="1">2016<sup><xref ref-type="bibr" rid="CR114">114</xref></sup></td></tr><tr><td colspan="1" rowspan="1"><p>Microvesicle</p><p><italic toggle="yes">Bacteroides</italic> spp.)</p><p>F1-V</p></td><td colspan="1" rowspan="1">OMV</td><td colspan="1" rowspan="1">self</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">p.o./i.n.</td><td colspan="1" rowspan="1">Not tested</td><td colspan="1" rowspan="1">Not tested</td><td colspan="1" rowspan="1">Robust IgA and IgG in blood and airways</td><td colspan="1" rowspan="1">2019<sup><xref ref-type="bibr" rid="CR80">80</xref></sup></td></tr><tr><td colspan="9" rowspan="1"><bold>Heterologous prime-boost</bold></td></tr><tr><td colspan="1" rowspan="1"><bold>Vaccine</bold></td><td colspan="1" rowspan="1"><bold>Type</bold></td><td colspan="1" rowspan="1"><bold>Adjuvant</bold></td><td colspan="1" rowspan="1"><bold>Doses</bold></td><td colspan="1" rowspan="1"><bold>Route</bold></td><td colspan="2" rowspan="1"><bold>Efficacy in mice</bold></td><td colspan="1" rowspan="1"><bold>Type of immune response</bold></td><td colspan="1" rowspan="1"><bold>Years Studied (Ref)</bold></td></tr><tr><td colspan="1" rowspan="1">Ad5-YFV/LMA<italic toggle="yes">**</italic></td><td colspan="1" rowspan="1">Hetero-logous</td><td colspan="1" rowspan="1">self</td><td colspan="1" rowspan="1">1&#8201;+&#8201;1</td><td colspan="1" rowspan="1">Both i.n.</td><td colspan="2" rowspan="1">Pneumonic &amp; bubonic</td><td colspan="1" rowspan="1">Ab and CMI</td><td colspan="1" rowspan="1">2021&#8211;2023<sup><xref ref-type="bibr" rid="CR56">56</xref></sup></td></tr></tbody></table><table-wrap-foot><p>Single asterisk indicates that only 50% of controls died. Double asterisk indicates that no clinical signs were observed in cynomolgus macaques or in African green monkeys; dollar sign indicates that Ad5 pre-existing immunity was induced prior to immunisation. <italic toggle="yes">OMV</italic> outer membrane vesicles, <italic toggle="yes">Ad5-YFV/LMA</italic> Ad-vectored and live attenuated, <italic toggle="yes">Ab</italic> Antibody, <italic toggle="yes">CMI</italic> cell-mediated immunity, <italic toggle="yes">s.c.</italic> sub-cutaneous, <italic toggle="yes">i.m.</italic> intra-muscular, <italic toggle="yes">i.n.</italic> intra-nasal, <italic toggle="yes">p.o.</italic> oral.</p></table-wrap-foot></table-wrap><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Plague vaccines in clinical trials.</title><p>*Adjuvant not specified. Ages of study participants ranges from 18 to 55 years. All vaccines were given in 2&#8211;3 doses intramuscularly over a range of 6 months. The EV 76 NIIEG vaccine was given 1&#8211;4 times at intervals of 1&#8211;3 months. ?data not published; !data not conclusive.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2040" position="float" orientation="portrait" xlink:href="41541_2024_958_Fig2_HTML.jpg"/></fig></p><sec id="Sec8"><title>Subunit</title><p id="Par22">Many groups have now shown that immunization with the F1 and V subunit antigens provides a high degree of protection against infection caused by <italic toggle="yes">Y. pestis</italic> in a range of animal models<sup><xref ref-type="bibr" rid="CR68">68</xref>&#8211;<xref ref-type="bibr" rid="CR78">78</xref></sup>. The use of F1 and V in combination (F1&#8201;+&#8201;V) or as a genetic fusion (F1-V) has the advantage that protection can be maintained against acapsular (F1-negative) <italic toggle="yes">Y. pestis</italic> strains which still retain virulence<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>. Many different formulations have been researched with a view to finding one that provides comprehensive protection with the least number of doses, is stable, and maintains immunogenicity when escalated up the species from mice to humans. These candidate vaccines which have been studied in much more detail are summarized in Table <xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par23">Adjuvants used in preclinical rF1V vaccine development studies include the toll-like receptor 5 (TLR5) ligand flagellin and protollin<sup><xref ref-type="bibr" rid="CR73">73</xref>&#8211;<xref ref-type="bibr" rid="CR75">75</xref></sup>. Packaged in a polyanhydride nanoparticle with cyclic dinucleotide and delivered as a single dose intranasally, rF1V protected mice against pneumonic plague<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. A truncated form of rV (rV10) has also been shown to be protective, as has rV10 in manganese silicate nanoparticles<sup><xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR77">77</xref></sup>. Similarly, the peptidoglycan-free outer membrane vesicles (OMV) with a phage lytic system has been demonstrated to be efficacious<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>, as have microvesicles derived from human commensal gut bacteria for immunization with V antigen<sup><xref ref-type="bibr" rid="CR80">80</xref></sup> or OMV&#8217;s from <italic toggle="yes">Y. pseudotuberculosis</italic><sup><xref ref-type="bibr" rid="CR81">81</xref></sup>. A dry formulation of rF1+rV delivered on calcium phosphate-decorated microparticles demonstrated enhanced immunogenicity and efficacy<sup><xref ref-type="bibr" rid="CR82">82</xref></sup>.</p><p id="Par24">A study has shown that the polymeric form of F1 led to rapid protective humoral immune response by activating innate-like B1b cells<sup><xref ref-type="bibr" rid="CR83">83</xref></sup> (Table <xref rid="Tab2" ref-type="table">2</xref>), and further observations suggested that this activation was unaffected by the presence of the V antigen in an admixture of F1 and V<sup><xref ref-type="bibr" rid="CR83">83</xref></sup>. Recent research has evaluated the impact of the administration of synthetic immunomodulating peptides on the survival of mice and guinea pigs subsequently exposed to virulent <italic toggle="yes">Y. pestis</italic><sup><xref ref-type="bibr" rid="CR84">84</xref></sup>. Administered in three doses prior to animal challenge, two immunomodulators were found to have a positive impact on survival; these were an azoximer bromide (polyoxidonium) and rIFN&#947;<sup><xref ref-type="bibr" rid="CR84">84</xref></sup>. Another study has shown that co-formulation of the rF1-V vaccine with recombinant human (rhIL2) and/or recombinant murine GM-CSF in alhydrogel enhanced immunogenicity and efficacy against a lethal aerosol challenge in mice<sup><xref ref-type="bibr" rid="CR85">85</xref></sup>.</p><p id="Par25">In April 2024, the Russian state regulator granted a marketing authorization<sup><xref ref-type="bibr" rid="CR86">86</xref></sup> for a single sub-cutaneous dose microencapsulated molecular plague vaccine (PMMM) comprising 25&#8211;30&#8201;&#181;g each of rF1 and rV in 4&#8211;6&#8201;mg polylactide, with the excipients polyvinyl alcohol, alhydrogel, polyvinyl pyrrolidine, polysorbate in phosphate buffered saline and containing 30&#8211;60&#8201;&#181;g thiomersal.</p></sec><sec id="Sec9"><title>Live attenuated</title><p id="Par26">The live attenuated vaccine (LAV) strain EV76-NIIEG has been used for human vaccination in Russia and China for many years to prevent or curtail outbreaks of plague<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Recently, the experimental evaluation of polyoxidonium co-administered with EV76 in a murine model has been shown to improve efficacy<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>.</p><p id="Par27">In addition to the live vaccine strain EV76, various deletion mutants of <italic toggle="yes">Y. pestis</italic> CO92 have been demonstrated to be efficacious in rodent models of pneumonic plague<sup><xref ref-type="bibr" rid="CR88">88</xref>&#8211;<xref ref-type="bibr" rid="CR91">91</xref></sup> (Table <xref rid="Tab3" ref-type="table">3</xref>). Among these, LMA and LMP mutants (deleted for genes encoding Braun lipoprotein [Lpp], methylacyl transferase B [MsbB], and either Attachment-invasion locus [Ail] or Plasminogen-activating protease [Pla], were of note, as they triggered robust humoral and cell-mediated immune responses in mice and were eliminated from the animals within 12&#8211;24&#8201;h<sup><xref ref-type="bibr" rid="CR88">88</xref>&#8211;<xref ref-type="bibr" rid="CR91">91</xref></sup>. Importantly, these mutants remained avirulent under iron-overload conditions<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. Further, a heterologous prime-boost strategy using one dose each of LMA or LMP and replication-defective adenovius5-based three component vaccine containing genes for YscF, F1, and LcrV (Ad5-YFV) administered in any order was highly efficacious with complete protection in mice in a pneumonic plague model<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> providing safety and combined benefits of subunit and live-attenuated vaccines (Table <xref rid="Tab5" ref-type="table">5</xref>). Likewise, EV76 vaccine deleted for Pla<sup><xref ref-type="bibr" rid="CR92">92</xref></sup> has shown promise. Recent work has also addressed the possibility of further attenuation of <italic toggle="yes">Y. pestis</italic> to serve as a vaccine<sup><xref ref-type="bibr" rid="CR93">93</xref></sup>. The two most protective vaccine candidates were <italic toggle="yes">Y. pestis</italic> CO92 mutants that were either cured for the <italic toggle="yes">pgm</italic> locus and the pPst plasmid or deleted for the <italic toggle="yes">yscN</italic> gene. These mutants completely protected BALB/c mice against subcutaneous and aerosol challenge with <italic toggle="yes">Y. pestis</italic><sup><xref ref-type="bibr" rid="CR93">93</xref>&#8211;<xref ref-type="bibr" rid="CR95">95</xref></sup> (Table <xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec10"><title>Vectored</title><p id="Par28">Since the potential to harness rDNA technology to produce vaccines in the 1980s, many more candidate plague vaccines have been pursued<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR96">96</xref>&#8211;<xref ref-type="bibr" rid="CR116">116</xref></sup>, including the use of attenuated bacterial or viral vectors to deliver antigens derived from <italic toggle="yes">Y. pestis</italic>. Vectors being evaluated include: <italic toggle="yes">Salmonella</italic>, <italic toggle="yes">Yersinia pseudotuberculosis</italic>, <italic toggle="yes">Lactobacillus</italic>, adenovirus, vesicular stomatitis virus, and vaccinia virus. Some of these well-studied vaccine candidates have been summarized in Table <xref rid="Tab4" ref-type="table">4</xref>.</p><p id="Par29">A common advantage of these vectors is that because they are live, but replication-deficient, only 1 or 2 doses of vaccine may be required to achieve protective immunity. A second advantage is that these vectored vaccines can be multivalent, expressing antigens from different pathogens and can deliver these antigens intracellularly, mimicking infection and inducing appropriate immunity. All of these vaccine vectors require an in vivo promoter to switch on the expression of a heterogenous antigen(s) to induce an immune response. The efficiency of the promoter and the molecular size of the expressed protein-encoding genes, together with need for post-transcriptional modifications such as glycosylation, determine the level and potency of the expressed vaccine antigens. Potential disadvantages of live vaccine vectors are the necessity of stable attenuation, the risk of use in immunocompromised individuals, the possibility of inducing immunity, or pre-existing immunity to the vector itself; however, the latter can be overcome by modification of the vector or by employing a heterologous prime-boost approach to prevent reduced responses on repeated use of the same vector<sup><xref ref-type="bibr" rid="CR99">99</xref>,<xref ref-type="bibr" rid="CR100">100</xref></sup> as we have recently shown<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. Further, our study in non-human primates showed that inducing pre-existing antibodies to Ad5 did not alter protective immune responses in a pneumonic plague model<sup><xref ref-type="bibr" rid="CR114">114</xref></sup>.</p></sec><sec id="Sec11"><title>Bacterial</title><p id="Par30">A substantial amount of research has been devoted to the development of <italic toggle="yes">Y. pseudotuberculosis</italic> as a vaccine for plague by deleting three essential virulence factors (High Pathogenicity Island, pH6 antigen, and YopK toxin) and by the insertion of the <italic toggle="yes">caf</italic> operon into the chromosome, allowing the production of an F1 pseudocapsule<sup><xref ref-type="bibr" rid="CR101">101</xref>&#8211;<xref ref-type="bibr" rid="CR104">104</xref></sup>. A <italic toggle="yes">Y. pseudotuberculosis</italic> construct (VTnF1) modified to maximize stability was immunogenic and efficacious against pneumonic plague in mice after a single oral dose<sup><xref ref-type="bibr" rid="CR102">102</xref></sup>, and generated humoral and cell-mediated immune responses<sup><xref ref-type="bibr" rid="CR103">103</xref></sup>. Subsequently, the VTnF1 vaccine has been shown to be effective in mice after subcutaneous injection and protects fully against injected (10<sup>4</sup> LD<sub>50</sub>) or 80% of animals against aerosolized (3300 LD<sub>50</sub>) <italic toggle="yes">Y. pestis</italic> CO92<sup><xref ref-type="bibr" rid="CR104">104</xref></sup> (Table <xref rid="Tab4" ref-type="table">4</xref>).</p><p id="Par31">Likewise, outer membrane vesicles (OMV) produced from a mutated version of <italic toggle="yes">Y. pseudotuberculosis</italic> expressing V and a modified version of LPS have been shown to be protective in mice against pneumonic plague<sup><xref ref-type="bibr" rid="CR105">105</xref></sup> (Table <xref rid="Tab4" ref-type="table">4</xref>).</p><p id="Par32">There has also been substantial research investment in <italic toggle="yes">Salmonella</italic> Typhi as a vaccine vector, particularly with its potential as an oral vaccine for plague. Early studies showed that the successful carriage by <italic toggle="yes">S</italic>. Typhimurium of the F1-encoding plasmid resulted in F1 protein secretion by <italic toggle="yes">S</italic>. Typhimurium, with visualization of the capsule surrounding the bacteria<sup><xref ref-type="bibr" rid="CR106">106</xref></sup>. However, whilst immunogenicity and efficacy were achieved, sustaining the vector in vivo to retain plasmids with sufficient gene expression over time without causing salmonellosis, has been an enduring challenge<sup><xref ref-type="bibr" rid="CR107">107</xref>,<xref ref-type="bibr" rid="CR108">108</xref></sup>. More recently, combinations of F1, Psn (pesticin receptor), and V antigen delivered orally to mice using mutant strains of <italic toggle="yes">S</italic>. Typhimurium have provided 100% protection against subcutaneous challenge with 570 LD<sub>50</sub> of <italic toggle="yes">Y. pestis</italic> CO92, but only 40-60% efficacy against 50 LD<sub>50</sub> of aerosolized <italic toggle="yes">Y. pestis</italic> CO92<sup><xref ref-type="bibr" rid="CR109">109</xref></sup>. Moreover, <italic toggle="yes">S</italic>. Typhimurium deleted for the genes <italic toggle="yes">lpp</italic> and <italic toggle="yes">msbB</italic> and used to express F1, LcrV, a combination of F1 and LcrV, and a combination of YscF and YopD, protected mice against <italic toggle="yes">Y. pestis</italic> CO92 infection in a pneumonic plague model<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR110">110</xref></sup>.</p><p id="Par33">Expression of genes encoding F1 and LcrV of <italic toggle="yes">Y. pestis</italic> and protective antigen (PA) of <italic toggle="yes">Bacillus anthracis</italic> in a <italic toggle="yes">Francisella tularensis</italic> LVS vaccine strain provided protection to mice against all three Tier-1 select agents, raising the prospect of a polyvalent biodefense vaccine<sup><xref ref-type="bibr" rid="CR111">111</xref></sup> (Table <xref rid="Tab4" ref-type="table">4</xref>).</p><p id="Par34">Bacteriophage T4 serves as an excellent nanoparticle platform to deliver plague immunogens (F1 and V as well as PA antigen of <italic toggle="yes">B. anthracis</italic>). Both mice and rats immunized with T4 phages without any adjuvant and harboring <italic toggle="yes">Y. pestis</italic> and <italic toggle="yes">B. anthracis</italic> immunogens were protective against pneumonic plague and lethal toxin intoxication when administered sequentially or simultaneously<sup><xref ref-type="bibr" rid="CR112">112</xref></sup> (Table <xref rid="Tab4" ref-type="table">4</xref>).</p></sec><sec id="Sec12"><title>Viral</title><p id="Par35">Recent preclinical studies have shown that vaccination of mice with Ad5-YFV provided complete protection to mice in a pneumonic plague model when challenge occurred with the F1-minus strain of <italic toggle="yes">Y. pestis</italic> CO92<sup><xref ref-type="bibr" rid="CR113">113</xref></sup>. This is when compared to animals that were vaccinated with the monovalent, Ad5-LcrV-based vaccine, and challenged with the F1-minus strain of <italic toggle="yes">Y. pestis</italic> CO92 where anti-F1-antibodies were rendered ineffective<sup><xref ref-type="bibr" rid="CR113">113</xref></sup>. This Ad5-YFV vaccine resulted in robust humoral and cell-mediated immune responses<sup><xref ref-type="bibr" rid="CR114">114</xref></sup>. The above vaccine also provided 100% protection to Cynomolgus macaques at a very high challenge dose of <italic toggle="yes">Y. pestis</italic> CO92 administered by the aerosol route<sup><xref ref-type="bibr" rid="CR114">114</xref></sup> (Tables <xref rid="Tab4" ref-type="table">4</xref> and <xref rid="Tab5" ref-type="table">5</xref>). An earlier version of Ad5-based vaccine harbored genes for F1 and LcrV and was shown to be protective in a murine pneumonic plague model<sup><xref ref-type="bibr" rid="CR115">115</xref>,<xref ref-type="bibr" rid="CR116">116</xref></sup>.</p><p id="Par36">A chimpanzee adenovirus vector (ChAdOX1) vaccine expressing F1 and V has been developed by the Oxford Vaccine Group. The ChAdOX1 vector is a replication-deficient adenoviral vector based on the simian adenovirus type Y25, originally chosen to avoid pre-existing adenovirus immunity in the human population<sup><xref ref-type="bibr" rid="CR117">117</xref></sup>. The phase 1 clinical trial started on this ChAdOX1 plague vaccine in 2021<sup><xref ref-type="bibr" rid="CR118">118</xref></sup> (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).</p></sec><sec id="Sec13"><title>DNA</title><p id="Par37">DNA-based plague vaccines comprising F1 and LcrV have also been tested and found to be immunogenic and protective (Table <xref rid="Tab4" ref-type="table">4</xref>). In an earlier study, we have shown that mice immunized with plasmid vectors containing genes for F1, LcrV, with a gene for LT (heat-labile enterotoxin as an adjuvant) were protective against pneumonic plague<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. In this report, mice were immunized with recombinant plasmids coated with 1.6-&#956;m gold particles and shot with the gene gun on the ears. The animals were immunized on days 0 and 3 months before intranasal challenge after 8 months following the last boost with <italic toggle="yes">Y. pestis</italic> CO92<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>.</p><p id="Par38">A DNA vaccine designed to protect against both anthrax and plague was evaluated in mice<sup><xref ref-type="bibr" rid="CR119">119</xref></sup>. DNA constructs comprising fusions of V with a truncated anthrax lethal factor (LF) or LF with F1 or V alone, were coated to gold nanoparticles and delivered by gene gun to A/J mice and were shown to protect fully against challenge 21days later wth aerosolized <italic toggle="yes">B. anthracis</italic> and to 80% against aerosolised <italic toggle="yes">Y. pestis</italic><sup><xref ref-type="bibr" rid="CR119">119</xref></sup>.</p></sec><sec id="Sec14"><title>mRNA</title><p id="Par39">More recently, mRNA technology has been extended to produce candidate plague vaccines. An mRNA vaccine expressing a circularly permutated form of F1 delivered in lipid nanoparticles (LNP) protected (100%) of mice against bubonic disease after only a single dose<sup><xref ref-type="bibr" rid="CR120">120</xref></sup>, whilst a self-amplifying mRNA LNP vaccine expressing both F1 and V was immunogenic in 2 doses and also protected outbred mice against a recent clinical isolate of <italic toggle="yes">Y. pestis</italic> from Madagascar in a bubonic plague model<sup><xref ref-type="bibr" rid="CR121">121</xref></sup>. Both of these vaccines induced humoral and cell-mediated immune responses (Table <xref rid="Tab4" ref-type="table">4</xref>) and show promise for future development, allowing a very flexible platform into which additional or modified RNA could be added, if needed. Furthermore, rapid advances in large scale manufacturing and formulation achieved for mRNA vaccines for SARS-CoV-2 are now readily transferrable to the plague application<sup><xref ref-type="bibr" rid="CR122">122</xref></sup>.</p></sec></sec><sec id="Sec15"><title>Translation to clinical development</title><p id="Par40">Some vaccine approaches discussed above have transitioned to early clinical development (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Currently, a formulation of recombinant F1V (rF1V) in alum, supplemented with CpG 1018 is in Phase 2 clinical trial (Dynavax, USA)<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. This form of CpG has already been incorporated in a Hepatitis B vaccine and approved by the FDA for clinical use in adults<sup><xref ref-type="bibr" rid="CR123">123</xref></sup>. Also in phase 2 clinical trial is a formulation of native F1 with rV in alum (Lanzhou Institute and Jiangsu Provincial CDC, China)<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. The third subunit vaccine currently in Phase 1 clinical trial comprises rF1V adjuvanted with flagellin (National Institute of Allergy and Infectious Diseases, USA)<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR124">124</xref></sup>.</p><p id="Par41">The EV76-NIIEG vaccine is still approved only in China and Russia where it is in Phase 4 clinical trial. Since 2002, there have been vaccination campaigns with EV76 in 16-18 provinces of Mongolia by the National Centre for Zoonotic Diseases, Ulaanbaatar, Mongolia<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. In a vaccination campaign report from plague-endemic foci in Mongolia, an adverse event rate of 7.3% with a 5.6% breakthrough in protection has been reported<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. In October 2023, there was an ongoing campaign with EV76 in Mongolia in response to an outbreak of plague<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p></sec><sec id="Sec16"><title>Strategies to gain evidence of vaccine efficacy</title><p id="Par42">As with nearly all clinical prophylaxes or therapies, the pathway to regulatory approval is time-consuming, expensive and difficult, requiring evidence (direct, indirect or deduced) of human efficacy. This is especially challenging for vaccines against Tier-1 select agents such as <italic toggle="yes">Y. pestis</italic>, as human challenge studies are unethical. Further, due to the endemic nature of the disease, the number of infected patients is not large enough to draw meaningful conclusions on vaccine efficacy. Here we review the strategies available to demonstrate vaccine efficacy for plague.</p></sec><sec id="Sec17"><title>Animal data to support licensing</title><p id="Par43">Because of the pathogenicity of <italic toggle="yes">Y. pestis</italic>, its potential for epidemic spread, and the unpredictable nature and size of regional plague outbreaks, the feasibility of Phase 3 trials, whether preventive or reactive in nature, is under discussion<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Even in Madagascar, where the plague season is well known, the number of cases involved varies, so a Phase 3 trial may not be sufficiently powered, unless successive seasons are used. Pathways to licensure may therefore comprise the scrutiny of immunogenicity and efficacy data generated in animal models under Good Laboratory Practice (GLP) using the FDA&#8217;s Animal rule<sup><xref ref-type="bibr" rid="CR125">125</xref></sup> with the human immunogenicity data generated in clinical trials (<italic toggle="yes">i.e</italic>. immunobridging)<sup><xref ref-type="bibr" rid="CR126">126</xref></sup> (Fig. <xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Immunobridging to predict vaccine efficacy in man.</title><p>The figure depicts the use of percentage survival in vaccinated animals, which correlates with an immunological readout(s), to compare with the same immunological readout determined in a clinical trial, to predict vaccine efficacy in human.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2615" position="float" orientation="portrait" xlink:href="41541_2024_958_Fig3_HTML.jpg"/></fig></p><p id="Par44">Evidence of efficacy could then be gained post-licensure. There is precedent for this with the Marketing Authorization under exceptional circumstances of an Ebola vaccine by the European Medicines Agency on the basis of human serum antibody data<sup><xref ref-type="bibr" rid="CR127">127</xref></sup>. The FDA also has an accelerated approval pathway but cautions that the bar for approval of a vaccine for the pneumonic indication would be set higher than for the bubonic indication<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p></sec><sec id="Sec18"><title>Immunobridging from animal models to human</title><p id="Par45">The vaccine approaches reviewed here have predominantly been screened in mice (outbred as well as inbred)<sup><xref ref-type="bibr" rid="CR128">128</xref></sup>, with some in Brown Norway rats<sup><xref ref-type="bibr" rid="CR112">112</xref>,<xref ref-type="bibr" rid="CR129">129</xref></sup> and a few in NHPs<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR114">114</xref>,<xref ref-type="bibr" rid="CR130">130</xref></sup> all of which are authentic models for plague and evaluate both antibody and cell-mediated immunity<sup><xref ref-type="bibr" rid="CR131">131</xref></sup>. The most consistent NHP model is the cynomolgus macaque<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR114">114</xref></sup>. However, increasing diversity in response occurs with escalation up to NHPs and the human population<sup><xref ref-type="bibr" rid="CR132">132</xref></sup>. Table <xref rid="Tab5" ref-type="table">5</xref> summarises the studies which have been performed in NHPs to determine the efficacy of vaccines which are in preclinical development.</p></sec><sec id="Sec19"><title>Immune correlates of protection and surrogate markers of efficacy</title><p id="Par46">Many researchers have now shown that antibody titers to the F1 and V proteins correlate with protection against bubonic and pneumonic plague in a range of animal models<sup><xref ref-type="bibr" rid="CR66">66</xref>,<xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR69">69</xref></sup>, but the induction of cell-mediated immunity (CMI)<sup><xref ref-type="bibr" rid="CR131">131</xref>,<xref ref-type="bibr" rid="CR132">132</xref></sup> and particularly a balanced Th1/Th2 response<sup><xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR93">93</xref>,<xref ref-type="bibr" rid="CR103">103</xref>,<xref ref-type="bibr" rid="CR133">133</xref>,<xref ref-type="bibr" rid="CR134">134</xref></sup> provides an optimal strategy for protection. The observation, <italic toggle="yes">inter alia</italic>, that mice immunized with the rF1-V vaccine and depleted of TNF&#945; and IFN&#947; just prior to challenge, had poor survival compared with immunized controls which were not depleted<sup><xref ref-type="bibr" rid="CR135">135</xref></sup> indicated key roles for these Th1 cytokines in the development of protective immunity and these cumulative data have spurred the formulation of vaccine candidates which induce appropriately balanced immunity.</p><p id="Par47">To enable effective immunobridging of animal data to human, it is preferable that researchers and developers use similar approaches to the measurement of antibody and cell-mediated responses<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR126">126</xref>,<xref ref-type="bibr" rid="CR132">132</xref></sup>. The assay of specific antibody titers by quantitative ELISA (including the species-agnostic BRIDGE ELISA)<sup><xref ref-type="bibr" rid="CR69">69</xref></sup> is clearly important and provides a convenient surrogate marker of efficacy in the clinic.</p><p id="Par48">Of equal importance is to assess cell-mediated immunity by ex vivo recall assay on animal tissue or human whole blood samples (by ELIspot or by flow cytometry)<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR103">103</xref>,<xref ref-type="bibr" rid="CR136">136</xref></sup> to determine the establishment of immune memory, and hence the need and spacing of booster doses. The ability also to assay for the induction of functional antibodies has been facilitated by the development of neutralizing monoclonal antibodies, particularly to V, enabling the development of competitive ELISAs<sup><xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR137">137</xref>&#8211;<xref ref-type="bibr" rid="CR139">139</xref></sup>, which may be important aids in the down-selection of promising candidates in research. There is also ongoing effort to establish human reference serum for plague to provide an international standard as a reference point for serological surrogate markers of efficacy and thus to enable vaccine development<sup><xref ref-type="bibr" rid="CR140">140</xref></sup>.</p><p id="Par49">The WHO has published a draft target product profile (TPP) for a future plague vaccine, which sets out the qualifying criteria in terms of schedule, administration route, presentation, target efficacies in reactive and preventive modes, stability, and coverage, which would be applied to any plague vaccine candidate<sup><xref ref-type="bibr" rid="CR141">141</xref></sup>.</p></sec><sec id="Sec20"><title>Future prospects</title><p id="Par50">As highlighted in this review, there are some very promising vaccine candidates in the development pipeline with the potential to prevent plague in vulnerable populations. Here, we have also highlighted the epidemic potential of this disease and of <italic toggle="yes">Y. pestis</italic>, which in the absence of an approved vaccine, remains a serious biothreat. Seasonal outbreaks in Madagascar and other endemic regions cause fatalities every year. The potential for climate change to enhance this human vulnerability to plague in endemic regions or beyond is also being closely monoitored<sup><xref ref-type="bibr" rid="CR142">142</xref>,<xref ref-type="bibr" rid="CR143">143</xref></sup>. Climate change has already affected other zoonoses by extending the vector species to cause outbreaks of chikungunya and zika viruses in Central and South America<sup><xref ref-type="bibr" rid="CR144">144</xref>,<xref ref-type="bibr" rid="CR145">145</xref></sup>.</p><p id="Par51">Aside from the difficulties of achieving statistically valid evidence of human efficacy, candidate vaccines may also fail because their manufacturing cannot be achieved at scale due to expense or feasibility. Thus, these promising candidate vaccines for plague are vulnerable to languish in the &#8216;valley of death&#8217; without sustained and sufficient funding for clinical development and manufacturing at scale. Post COVID-19, the WHO has recently commented that &#8216;despite some recent progress, public heath vaccines are not available in all global regions and vaccines which have been prioritized by the WHO are not being developed or fully invested in, due to limited profit potential.&#8217;<sup><xref ref-type="bibr" rid="CR146">146</xref></sup> The Immunization Agenda 2030 endorsed by the WHO has a goal to reduce the incidence of, or to prevent, epidemics caused by vector-borne diseases by 2030<sup><xref ref-type="bibr" rid="CR147">147</xref></sup>. These goals seem particularly relevant to plague prevention.</p><p id="Par52">To date, there has been a significant investment in time and money in the research and early development of new plague vaccines. It is to be hoped that all the R&amp;D activity on plague vaccines, which emerged after the decline in use of KWC vaccines, will be sustained and together with the regulatory pathways currently being mapped out, will lead to the approval of some new, safe, and fully efficacious vaccines to reduce disease prevalence. We recommend that global funding and health security systems take ambitious action to realize the potential of this investment in an approved vaccine(s) for plague.</p></sec></sec><sec id="Sec21" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41541_2024_958_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41541-024-00958-1.</p></sec><ack><title>Acknowledgements</title><p>E.D.W. would like to thank Prof. Tim Atkins, Prof. Riccardo d&#8217;Elia and Dr. Tom Laws for their review of the draft. Funding through the NIH (AI064389, AI153524 and AI071634) awarded to A.K.C. is gratefully acknowledged. Funding for PBK through an NIH T32 AI179595 postdoctoral fellowship in the Antimicrobial Resistance Training Program of the Texas Medical Center (AMR-TPT) is also acknowledged.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>E.D.W. and A.K.C contributed equally to the preparation of the manuscript. All authors have read and approved the manuscript. P.B.K., E.K.H., B.H.N., and J.S. performed literature search, prepared tables and Fig. <xref rid="Fig2" ref-type="fig">2</xref> and edited the review.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par53">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brubaker</surname><given-names>B</given-names></name></person-group><article-title>Factors promoting acute and chronic diseases caused by yersiniae</article-title><source>Clin. Microbiol Rev.</source><year>1991</year><volume>4</volume><fpage>309</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1128/CMR.4.3.309</pub-id><pub-id pub-id-type="pmid">1889045</pub-id><pub-id pub-id-type="pmcid">PMC358201</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Brubaker, B. Factors promoting acute and chronic diseases caused by yersiniae. <italic toggle="yes">Clin. Microbiol Rev.</italic><bold>4</bold>, 309&#8211;324 (1991).<pub-id pub-id-type="pmid">1889045</pub-id><pub-id pub-id-type="doi">10.1128/CMR.4.3.309</pub-id><pub-id pub-id-type="pmcid">PMC358201</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollitzer</surname><given-names>R</given-names></name></person-group><article-title>Plague</article-title><source>World Health Organ Monogr. Ser.</source><year>1954</year><volume>22</volume><fpage>1</fpage><lpage>698</lpage></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Pollitzer, R. Plague. <italic toggle="yes">World Health Organ Monogr. Ser.</italic><bold>22</bold>, 1&#8211;698 (1954).</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Global consultation on Plague Vaccines, WHO <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/events/detail/2023/10/12/default-calendar/global-consultation-on-plague-vaccines">https://www.who.int/news-room/events/detail/2023/10/12/default-calendar/global-consultation-on-plague-vaccines</ext-link> (2023).</mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doll</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona</article-title><source>Am. J. Trop. Med. Hyg.</source><year>1994</year><volume>5</volume><fpage>109</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1994.51.109</pub-id><pub-id pub-id-type="pmid">8059908</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Doll, J. M. et al. Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. <italic toggle="yes">Am. J. Trop. Med. Hyg.</italic><bold>5</bold>, 109&#8211;114 (1994).<pub-id pub-id-type="doi">10.4269/ajtmh.1994.51.109</pub-id><pub-id pub-id-type="pmid">8059908</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>RD</given-names></name><name name-style="western"><surname>Fetherston</surname><given-names>JD</given-names></name></person-group><article-title>Yersinia pestis&#8212;etiologic agent of plague</article-title><source>Clin. Microbiol Rev.</source><year>1997</year><volume>10</volume><fpage>35</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1128/CMR.10.1.35</pub-id><pub-id pub-id-type="pmid">8993858</pub-id><pub-id pub-id-type="pmcid">PMC172914</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Perry, R. D. &amp; Fetherston, J. D. Yersinia pestis&#8212;etiologic agent of plague. <italic toggle="yes">Clin. Microbiol Rev.</italic><bold>10</bold>, 35&#8211;66 (1997).<pub-id pub-id-type="pmid">8993858</pub-id><pub-id pub-id-type="doi">10.1128/CMR.10.1.35</pub-id><pub-id pub-id-type="pmcid">PMC172914</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Butler T. Plague and Other Yersinia Infections. (New York, Plenum Press, 1983).</mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Prevention of plague: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <italic toggle="yes">Morb. Mortal Wkly. Rep.</italic><bold>45</bold>, 1&#8211;15 (1996).<pub-id pub-id-type="pmid">8975114</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>ED</given-names></name><name name-style="western"><surname>Westlake</surname><given-names>GE</given-names></name></person-group><article-title>Vaccines for emerging pathogens: prospects for licensure. Review series on Vaccines for emerging pathogens: from research to the clinic Part 1</article-title><source>Clin. Exp. Immunol.</source><year>2019</year><volume>198</volume><fpage>170</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1111/cei.13284</pub-id><pub-id pub-id-type="pmid">30972733</pub-id><pub-id pub-id-type="pmcid">PMC6797873</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Williamson, E. D. &amp; Westlake, G. E. Vaccines for emerging pathogens: prospects for licensure. Review series on Vaccines for emerging pathogens: from research to the clinic Part 1. <italic toggle="yes">Clin. Exp. Immunol.</italic><bold>198</bold>, 170&#8211;183 (2019).<pub-id pub-id-type="pmid">30972733</pub-id><pub-id pub-id-type="doi">10.1111/cei.13284</pub-id><pub-id pub-id-type="pmcid">PMC6797873</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Randremanana</surname><given-names>R</given-names></name><etal/></person-group><article-title>Epidemiological characteristics of an urban plague epidemic in Madagascar, August-November, 2017: an outbreak report</article-title><source>Lancet Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>537</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30730-8</pub-id><pub-id pub-id-type="pmid">30930106</pub-id><pub-id pub-id-type="pmcid">PMC6483974</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Randremanana, R. et al. Epidemiological characteristics of an urban plague epidemic in Madagascar, August-November, 2017: an outbreak report. <italic toggle="yes">Lancet Infect. Dis.</italic><bold>19</bold>, 537&#8211;545 (2019).<pub-id pub-id-type="pmid">30930106</pub-id><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30730-8</pub-id><pub-id pub-id-type="pmcid">PMC6483974</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guiyoule</surname><given-names>A</given-names></name><etal/></person-group><article-title>Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis</article-title><source>Emerg. Infect. Dis.</source><year>2001</year><volume>7</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.3201/eid0701.010106</pub-id><pub-id pub-id-type="pmid">11266293</pub-id><pub-id pub-id-type="pmcid">PMC2631670</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Guiyoule, A. et al. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. <italic toggle="yes">Emerg. Infect. Dis.</italic><bold>7</bold>, 43&#8211;48 (2001).<pub-id pub-id-type="pmid">11266293</pub-id><pub-id pub-id-type="doi">10.3201/eid0701.010106</pub-id><pub-id pub-id-type="pmcid">PMC2631670</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galimand</surname><given-names>M</given-names></name><name name-style="western"><surname>Carniel</surname><given-names>E</given-names></name><name name-style="western"><surname>Courvalin</surname><given-names>P</given-names></name></person-group><article-title>Resistance of Y. pestis to antimicrobial agents</article-title><source>Antimicrob. Agents Chemother.</source><year>2006</year><volume>50</volume><fpage>3233</fpage><lpage>3236</lpage><pub-id pub-id-type="doi">10.1128/AAC.00306-06</pub-id><pub-id pub-id-type="pmid">17005799</pub-id><pub-id pub-id-type="pmcid">PMC1610074</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Galimand, M., Carniel, E. &amp; Courvalin, P. Resistance of Y. pestis to antimicrobial agents. <italic toggle="yes">Antimicrob. Agents Chemother.</italic><bold>50</bold>, 3233&#8211;3236 (2006).<pub-id pub-id-type="pmid">17005799</pub-id><pub-id pub-id-type="doi">10.1128/AAC.00306-06</pub-id><pub-id pub-id-type="pmcid">PMC1610074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Achtman</surname><given-names>M</given-names></name><etal/></person-group><article-title><italic toggle="yes">Yersinia pestis</italic>, the cause of plague, is a recently emerged clone of <italic toggle="yes">Yersinia pseudotuberculosis</italic></article-title><source>Proc. Natl Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>14043</fpage><lpage>14048</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.24.14043</pub-id><pub-id pub-id-type="pmid">10570195</pub-id><pub-id pub-id-type="pmcid">PMC24187</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Achtman, M. et al. <italic toggle="yes">Yersinia pestis</italic>, the cause of plague, is a recently emerged clone of <italic toggle="yes">Yersinia pseudotuberculosis</italic>. <italic toggle="yes">Proc. Natl Acad. Sci. USA</italic><bold>96</bold>, 14043&#8211;14048 (1999).<pub-id pub-id-type="pmid">10570195</pub-id><pub-id pub-id-type="doi">10.1073/pnas.96.24.14043</pub-id><pub-id pub-id-type="pmcid">PMC24187</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Poinar G. A new genus of fleas with associated microorganisms in Dominican amber. <italic toggle="yes">J.Med. Entomol</italic>. 126 10.1093/jme/tjv (2015).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jme/tjv134</pub-id><pub-id pub-id-type="pmid">26373892</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parkhill</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genome sequence of <italic toggle="yes">Yersinia pestis</italic>, the causative agent of plague</article-title><source>Nature</source><year>2001</year><volume>413</volume><fpage>523</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1038/35097083</pub-id><pub-id pub-id-type="pmid">11586360</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Parkhill, J. et al. Genome sequence of <italic toggle="yes">Yersinia pestis</italic>, the causative agent of plague. <italic toggle="yes">Nature</italic><bold>413</bold>, 523&#8211;552 (2001).<pub-id pub-id-type="pmid">11586360</pub-id><pub-id pub-id-type="doi">10.1038/35097083</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornelis</surname><given-names>GR</given-names></name><etal/></person-group><article-title>The virulence plasmid of Yersinia, an antihost genome</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>1998</year><volume>62</volume><fpage>1315</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1128/MMBR.62.4.1315-1352.1998</pub-id><pub-id pub-id-type="pmid">9841674</pub-id><pub-id pub-id-type="pmcid">PMC98948</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Cornelis, G. R. et al. The virulence plasmid of Yersinia, an antihost genome. <italic toggle="yes">Microbiol. Mol. Biol. Rev.</italic><bold>62</bold>, 1315&#8211;1352 (1998).<pub-id pub-id-type="pmid">9841674</pub-id><pub-id pub-id-type="doi">10.1128/MMBR.62.4.1315-1352.1998</pub-id><pub-id pub-id-type="pmcid">PMC98948</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornelis</surname><given-names>GR</given-names></name><etal/></person-group><article-title>The Yersinia yop regulon</article-title><source>Mol. Microbiol</source><year>1989</year><volume>3</volume><fpage>1455</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.1989.tb00129.x</pub-id><pub-id pub-id-type="pmid">2693899</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Cornelis, G. R. et al. The Yersinia yop regulon. <italic toggle="yes">Mol. Microbiol</italic><bold>3</bold>, 1455&#8211;1459 (1989).<pub-id pub-id-type="pmid">2693899</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2958.1989.tb00129.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Mikula K. M., Kolodziejczyk R., Goldman A. Yersinia infection tools&#8212;characterization of structure and function of adhesins. <italic toggle="yes">Frontiers in Cellular and Infection Microbiology</italic><bold>2</bold>, article 16; 10.3389/fcimb.2012.00169 (2013).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2012.00169</pub-id><pub-id pub-id-type="pmcid">PMC3539135</pub-id><pub-id pub-id-type="pmid">23316485</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Rosqvist</surname><given-names>R</given-names></name><name name-style="western"><surname>Forsberg</surname><given-names>A</given-names></name></person-group><article-title>Role of fraction 1 antigen of <italic toggle="yes">Yersinia pestis</italic> in inhibition of phagocytosis</article-title><source>Infect. Immun.</source><year>2002</year><volume>70</volume><fpage>1453</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.3.1453-1460.2002</pub-id><pub-id pub-id-type="pmid">11854232</pub-id><pub-id pub-id-type="pmcid">PMC127752</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Du, Y., Rosqvist, R. &amp; Forsberg, A. Role of fraction 1 antigen of <italic toggle="yes">Yersinia pestis</italic> in inhibition of phagocytosis. <italic toggle="yes">Infect. Immun.</italic><bold>70</bold>, 1453&#8211;146 (2002).<pub-id pub-id-type="pmid">11854232</pub-id><pub-id pub-id-type="doi">10.1128/IAI.70.3.1453-1460.2002</pub-id><pub-id pub-id-type="pmcid">PMC127752</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hinnesbusch</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Perry</surname><given-names>RD</given-names></name><name name-style="western"><surname>Schwan</surname><given-names>TG</given-names></name></person-group><article-title>Role of the <italic toggle="yes">Yersinia pestis</italic> hemin storage (hms) locus in the transmission of plague by fleas</article-title><source>Science</source><year>1996</year><volume>273</volume><fpage>367</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1126/science.273.5273.367</pub-id><pub-id pub-id-type="pmid">8662526</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Hinnesbusch, B. J., Perry, R. D. &amp; Schwan, T. G. Role of the <italic toggle="yes">Yersinia pestis</italic> hemin storage (hms) locus in the transmission of plague by fleas. <italic toggle="yes">Science</italic><bold>273</bold>, 367&#8211;370 (1996).<pub-id pub-id-type="pmid">8662526</pub-id><pub-id pub-id-type="doi">10.1126/science.273.5273.367</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hinnebusch</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Role of Yersinia murine toxin in survival of <italic toggle="yes">Yersinia pestis</italic> in the midgut of the flea vector</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>733</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1126/science.1069972</pub-id><pub-id pub-id-type="pmid">11976454</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hinnebusch, B. J. et al. Role of Yersinia murine toxin in survival of <italic toggle="yes">Yersinia pestis</italic> in the midgut of the flea vector. <italic toggle="yes">Science</italic><bold>296</bold>, 733&#8211;735 (2002).<pub-id pub-id-type="pmid">11976454</pub-id><pub-id pub-id-type="doi">10.1126/science.1069972</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hinnebusch</surname><given-names>BJ</given-names></name></person-group><article-title>Transmision factors: <italic toggle="yes">Yersinia pestis</italic> genes required to infect the flea vactor of plague</article-title><source>Adv. Exp. Med. Biol.</source><year>2003</year><volume>529</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1007/0-306-48416-1_11</pub-id><pub-id pub-id-type="pmid">12756729</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Hinnebusch, B. J. Transmision factors: <italic toggle="yes">Yersinia pestis</italic> genes required to infect the flea vactor of plague. <italic toggle="yes">Adv. Exp. Med. Biol.</italic><bold>529</bold>, 55&#8211;62 (2003).<pub-id pub-id-type="pmid">12756729</pub-id><pub-id pub-id-type="doi">10.1007/0-306-48416-1_11</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darby</surname><given-names>C</given-names></name><name name-style="western"><surname>Ananth</surname><given-names>SL</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name><name name-style="western"><surname>Hinnebusch</surname><given-names>BJ</given-names></name></person-group><article-title>Identification of gmhA, a <italic toggle="yes">Yersinia pestis</italic> gene required for flea blockage, by using a <italic toggle="yes">Caenorhabditis elegans</italic> biofilm system</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>7236</fpage><lpage>7242</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.11.7236-7242.2005</pub-id><pub-id pub-id-type="pmid">16239518</pub-id><pub-id pub-id-type="pmcid">PMC1273845</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Darby, C., Ananth, S. L., Tan, L. &amp; Hinnebusch, B. J. Identification of gmhA, a <italic toggle="yes">Yersinia pestis</italic> gene required for flea blockage, by using a <italic toggle="yes">Caenorhabditis elegans</italic> biofilm system. <italic toggle="yes">Infect. Immun.</italic><bold>73</bold>, 7236&#8211;7242 (2005).<pub-id pub-id-type="pmid">16239518</pub-id><pub-id pub-id-type="doi">10.1128/IAI.73.11.7236-7242.2005</pub-id><pub-id pub-id-type="pmcid">PMC1273845</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vadyvaloo</surname><given-names>V</given-names></name><etal/></person-group><article-title>Transit through the Flea Vector Induces a pretransmission innate immunity resistance phenotype in Yersinia pestis</article-title><source>PLoS Pathog.</source><year>2010</year><volume>6</volume><fpage>e1000783</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1000783</pub-id><pub-id pub-id-type="pmid">20195507</pub-id><pub-id pub-id-type="pmcid">PMC2829055</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Vadyvaloo, V. et al. Transit through the Flea Vector Induces a pretransmission innate immunity resistance phenotype in Yersinia pestis. <italic toggle="yes">PLoS Pathog.</italic><bold>6</bold>, e1000783 (2010).<pub-id pub-id-type="pmid">20195507</pub-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000783</pub-id><pub-id pub-id-type="pmcid">PMC2829055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavanaugh</surname><given-names>DC</given-names></name><name name-style="western"><surname>Randall</surname><given-names>R</given-names></name></person-group><article-title>The role of multiplication of <italic toggle="yes">Pasteurella pestis</italic> in mononuclear phagocytes in the pathogenesis of flea-borne plague</article-title><source>J. Immunol.</source><year>1959</year><volume>83</volume><fpage>348</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.83.4.348</pub-id><pub-id pub-id-type="pmid">13808585</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Cavanaugh, D. C. &amp; Randall, R. The role of multiplication of <italic toggle="yes">Pasteurella pestis</italic> in mononuclear phagocytes in the pathogenesis of flea-borne plague. <italic toggle="yes">J. Immunol.</italic><bold>83</bold>, 348&#8211;363 (1959).<pub-id pub-id-type="pmid">13808585</pub-id><pub-id pub-id-type="doi">10.4049/jimmunol.83.4.348</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindler</surname><given-names>LE</given-names></name><name name-style="western"><surname>Klemper</surname><given-names>MS</given-names></name><name name-style="western"><surname>Straley</surname><given-names>SC</given-names></name></person-group><article-title><italic toggle="yes">Yersinia pestis</italic> pH 6 antigen: Genetic, biochemical and virulence characterisation of a protein involved in the pathogenesis of bubonic plague</article-title><source>Infect. Immun.</source><year>1990</year><volume>58</volume><fpage>2569</fpage><lpage>2577</lpage><pub-id pub-id-type="doi">10.1128/iai.58.8.2569-2577.1990</pub-id><pub-id pub-id-type="pmid">2164509</pub-id><pub-id pub-id-type="pmcid">PMC258857</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Lindler, L. E., Klemper, M. S. &amp; Straley, S. C. <italic toggle="yes">Yersinia pestis</italic> pH 6 antigen: Genetic, biochemical and virulence characterisation of a protein involved in the pathogenesis of bubonic plague. <italic toggle="yes">Infect. Immun.</italic><bold>58</bold>, 2569&#8211;2577 (1990).<pub-id pub-id-type="pmid">2164509</pub-id><pub-id pub-id-type="doi">10.1128/iai.58.8.2569-2577.1990</pub-id><pub-id pub-id-type="pmcid">PMC258857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X-Z</given-names></name><name name-style="western"><surname>Lindler</surname><given-names>LE</given-names></name></person-group><article-title>The pH6 antigens is an antiphagocytic factor produced by <italic toggle="yes">Yersinia pestis</italic> independent of Yersinia outer proteins and capsular antigen</article-title><source>Infect. Immun.</source><year>2004</year><volume>72</volume><fpage>7212</fpage><lpage>7219</lpage><pub-id pub-id-type="doi">10.1128/IAI.72.12.7212-7219.2004</pub-id><pub-id pub-id-type="pmid">15557646</pub-id><pub-id pub-id-type="pmcid">PMC529099</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Huang, X.-Z. &amp; Lindler, L. E. The pH6 antigens is an antiphagocytic factor produced by <italic toggle="yes">Yersinia pestis</italic> independent of Yersinia outer proteins and capsular antigen. <italic toggle="yes">Infect. Immun.</italic><bold>72</bold>, 7212&#8211;7219 (2004).<pub-id pub-id-type="pmid">15557646</pub-id><pub-id pub-id-type="doi">10.1128/IAI.72.12.7212-7219.2004</pub-id><pub-id pub-id-type="pmcid">PMC529099</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>RC</given-names></name><name name-style="western"><surname>Gewurz</surname><given-names>H</given-names></name><name name-style="western"><surname>Quie</surname><given-names>PG</given-names></name></person-group><article-title>Effects of fraction 1 from <italic toggle="yes">Yersinia pestis</italic> on phagocytosis in vitro</article-title><source>J. Infect. Dis.</source><year>1972</year><volume>126</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1093/infdis/126.3.235</pub-id><pub-id pub-id-type="pmid">4559742</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Williams, R. C., Gewurz, H. &amp; Quie, P. G. Effects of fraction 1 from <italic toggle="yes">Yersinia pestis</italic> on phagocytosis in vitro. <italic toggle="yes">J. Infect. Dis.</italic><bold>126</bold>, 235&#8211;241 (1972).<pub-id pub-id-type="pmid">4559742</pub-id><pub-id pub-id-type="doi">10.1093/infdis/126.3.235</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sha</surname><given-names>J</given-names></name><etal/></person-group><article-title>Characterization of an F1 deletion mutant of <italic toggle="yes">Yersinia pestis</italic> CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capture-based dipsticks</article-title><source>J. Clin. Microbiol.</source><year>2011</year><volume>49</volume><fpage>1708</fpage><lpage>1715</lpage><pub-id pub-id-type="doi">10.1128/JCM.00064-11</pub-id><pub-id pub-id-type="pmid">21367990</pub-id><pub-id pub-id-type="pmcid">PMC3122665</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Sha, J. et al. Characterization of an F1 deletion mutant of <italic toggle="yes">Yersinia pestis</italic> CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capture-based dipsticks. <italic toggle="yes">J. Clin. Microbiol.</italic><bold>49</bold>, 1708&#8211;1715 (2011).<pub-id pub-id-type="pmid">21367990</pub-id><pub-id pub-id-type="doi">10.1128/JCM.00064-11</pub-id><pub-id pub-id-type="pmcid">PMC3122665</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Straley</surname><given-names>SC</given-names></name><name name-style="western"><surname>Skrzypek</surname><given-names>E</given-names></name><name name-style="western"><surname>Plano</surname><given-names>GV</given-names></name><name name-style="western"><surname>Bliska</surname><given-names>JB</given-names></name></person-group><article-title>Yops of Yersinia spp. pathogenic for humans</article-title><source>Infect. Immun.</source><year>1993</year><volume>61</volume><fpage>3105</fpage><lpage>3110</lpage><pub-id pub-id-type="doi">10.1128/iai.61.8.3105-3110.1993</pub-id><pub-id pub-id-type="pmid">8335339</pub-id><pub-id pub-id-type="pmcid">PMC280975</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Straley, S. C., Skrzypek, E., Plano, G. V. &amp; Bliska, J. B. Yops of Yersinia spp. pathogenic for humans. <italic toggle="yes">Infect. Immun.</italic><bold>61</bold>, 3105&#8211;3110 (1993).<pub-id pub-id-type="pmid">8335339</pub-id><pub-id pub-id-type="doi">10.1128/iai.61.8.3105-3110.1993</pub-id><pub-id pub-id-type="pmcid">PMC280975</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>CA</given-names></name><etal/></person-group><article-title>The V-antigens of Yersinia forms a distinct structure at the tip of injectisome needles</article-title><source>Science</source><year>2005</year><volume>310</volume><fpage>674</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1126/science.1118476</pub-id><pub-id pub-id-type="pmid">16254184</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Mueller, C. A. et al. The V-antigens of Yersinia forms a distinct structure at the tip of injectisome needles. <italic toggle="yes">Science</italic><bold>310</bold>, 674&#8211;676 (2005).<pub-id pub-id-type="pmid">16254184</pub-id><pub-id pub-id-type="doi">10.1126/science.1118476</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakajima</surname><given-names>R</given-names></name><name name-style="western"><surname>Brubaker</surname><given-names>RR</given-names></name></person-group><article-title>Association between virulence of <italic toggle="yes">Yersinia pestis</italic> and supression of gamma interferon and tumor necrosis factor alpha</article-title><source>Infect. Immun.</source><year>1993</year><volume>61</volume><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1128/iai.61.1.23-31.1993</pub-id><pub-id pub-id-type="pmid">8418045</pub-id><pub-id pub-id-type="pmcid">PMC302683</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Nakajima, R. &amp; Brubaker, R. R. Association between virulence of <italic toggle="yes">Yersinia pestis</italic> and supression of gamma interferon and tumor necrosis factor alpha. <italic toggle="yes">Infect. Immun.</italic><bold>61</bold>, 23&#8211;31 (1993).<pub-id pub-id-type="pmid">8418045</pub-id><pub-id pub-id-type="doi">10.1128/iai.61.1.23-31.1993</pub-id><pub-id pub-id-type="pmcid">PMC302683</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakajima</surname><given-names>R</given-names></name><name name-style="western"><surname>Motin</surname><given-names>VL</given-names></name><name name-style="western"><surname>Brubaker</surname><given-names>RR</given-names></name></person-group><article-title>Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunisation</article-title><source>Infect. Immun.</source><year>1995</year><volume>6</volume><fpage>3021</fpage><lpage>3029</lpage><pub-id pub-id-type="doi">10.1128/iai.63.8.3021-3029.1995</pub-id><pub-id pub-id-type="pmcid">PMC173411</pub-id><pub-id pub-id-type="pmid">7622225</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Nakajima, R., Motin, V. L. &amp; Brubaker, R. R. Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunisation. <italic toggle="yes">Infect. Immun.</italic><bold>6</bold>, 3021&#8211;3029 (1995).<pub-id pub-id-type="doi">10.1128/iai.63.8.3021-3029.1995</pub-id><pub-id pub-id-type="pmcid">PMC173411</pub-id><pub-id pub-id-type="pmid">7622225</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skurnik</surname><given-names>M</given-names></name><name name-style="western"><surname>Peippo</surname><given-names>A</given-names></name><name name-style="western"><surname>Ervela</surname><given-names>E</given-names></name></person-group><article-title>Characterization of the O antigen gene clusters of <italic toggle="yes">Yersinia pseudotuberculosis</italic> and the cryptic O antigen gene cluster of <italic toggle="yes">Yersinia pestis</italic> shows that the plague bacillus is most closely related to and has evolved from <italic toggle="yes">Y. pseudotuberculosis</italic> serotype O:1b</article-title><source>Mol. Microbiol.</source><year>2000</year><volume>37</volume><fpage>316</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2000.01993.x</pub-id><pub-id pub-id-type="pmid">10931327</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Skurnik, M., Peippo, A. &amp; Ervela, E. Characterization of the O antigen gene clusters of <italic toggle="yes">Yersinia pseudotuberculosis</italic> and the cryptic O antigen gene cluster of <italic toggle="yes">Yersinia pestis</italic> shows that the plague bacillus is most closely related to and has evolved from <italic toggle="yes">Y. pseudotuberculosis</italic> serotype O:1b. <italic toggle="yes">Mol. Microbiol.</italic><bold>37</bold>, 316&#8211;330 (2000).<pub-id pub-id-type="pmid">10931327</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2958.2000.01993.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prior</surname><given-names>JL</given-names></name><etal/></person-group><article-title>The failure of different strains of <italic toggle="yes">Yersinia pestis</italic> to produce lipopolysaccharide O antigen under different growth conditions is due to mutations in the O-antigen gene cluster</article-title><source>FEMS Microbiol Lett.</source><year>2001</year><volume>197</volume><fpage>229</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2001.tb10608.x</pub-id><pub-id pub-id-type="pmid">11313139</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Prior, J. L. et al. The failure of different strains of <italic toggle="yes">Yersinia pestis</italic> to produce lipopolysaccharide O antigen under different growth conditions is due to mutations in the O-antigen gene cluster. <italic toggle="yes">FEMS Microbiol Lett.</italic><bold>197</bold>, 229&#8211;233 (2001).<pub-id pub-id-type="pmid">11313139</pub-id><pub-id pub-id-type="doi">10.1111/j.1574-6968.2001.tb10608.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suomalainen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Temperature-induced changes in the lipopolysaccharide of Yersinia pestis affect plasminogen activation by the pla surface protease</article-title><source>Infect. Immun.</source><year>2010</year><volume>78</volume><fpage>2644</fpage><lpage>2652</lpage><pub-id pub-id-type="doi">10.1128/IAI.01329-09</pub-id><pub-id pub-id-type="pmid">20368351</pub-id><pub-id pub-id-type="pmcid">PMC2876559</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Suomalainen, M. et al. Temperature-induced changes in the lipopolysaccharide of Yersinia pestis affect plasminogen activation by the pla surface protease. <italic toggle="yes">Infect. Immun.</italic><bold>78</bold>, 2644&#8211;2652 (2010).<pub-id pub-id-type="pmid">20368351</pub-id><pub-id pub-id-type="doi">10.1128/IAI.01329-09</pub-id><pub-id pub-id-type="pmcid">PMC2876559</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kukkonen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lack of O-antigen is essential for plasminogen activation by <italic toggle="yes">Yersinia pestis</italic> and <italic toggle="yes">Salmonella enterica</italic></article-title><source>Mol. Microbiol.</source><year>2004</year><volume>51</volume><fpage>215</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03817.x</pub-id><pub-id pub-id-type="pmid">14651623</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Kukkonen, M. et al. Lack of O-antigen is essential for plasminogen activation by <italic toggle="yes">Yersinia pestis</italic> and <italic toggle="yes">Salmonella enterica</italic>. <italic toggle="yes">Mol. Microbiol.</italic><bold>51</bold>, 215&#8211;225 (2004).<pub-id pub-id-type="pmid">14651623</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03817.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kun</surname><given-names>Y</given-names></name><etal/></person-group><article-title><italic toggle="yes">Yersinia pestis</italic> Interacts with SIGNR1 (CD209b) for promoting host dissemination and infection</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00096</pub-id><pub-id pub-id-type="pmid">30915064</pub-id><pub-id pub-id-type="pmcid">PMC6422942</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Kun, Y. et al. <italic toggle="yes">Yersinia pestis</italic> Interacts with SIGNR1 (CD209b) for promoting host dissemination and infection. <italic toggle="yes">Front. Immunol.</italic><bold>10</bold>, 96 (2019).<pub-id pub-id-type="pmid">30915064</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00096</pub-id><pub-id pub-id-type="pmcid">PMC6422942</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">van Lier C. J. et al. Further characterization of a highly attenuated <italic toggle="yes">Yersinia pestis</italic> CO92 mutant deleted for the genes encoding Braun lipoprotein and plasminogen activator protease in murine alveolar and primary human macrophages. <italic toggle="yes">Microb. Pathog</italic>. <bold>80</bold>, 27&#8211;38 10.1016/j.micpath.2015.02.005.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micpath.2015.02.005</pub-id><pub-id pub-id-type="pmcid">PMC4363157</pub-id><pub-id pub-id-type="pmid">25697665</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sebbane</surname><given-names>F</given-names></name><etal/></person-group><article-title>The <italic toggle="yes">Yersinia pestis</italic> caf1M1A1 fimbrial capsule operon promotes transmission by flea bite in a mouse model of bubonic plague</article-title><source>Infect. Immun.</source><year>2009</year><volume>77</volume><fpage>1222</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1128/IAI.00950-08</pub-id><pub-id pub-id-type="pmid">19103769</pub-id><pub-id pub-id-type="pmcid">PMC2643634</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Sebbane, F. et al. The <italic toggle="yes">Yersinia pestis</italic> caf1M1A1 fimbrial capsule operon promotes transmission by flea bite in a mouse model of bubonic plague. <italic toggle="yes">Infect. Immun.</italic><bold>77</bold>, 1222&#8211;1229 (2009).<pub-id pub-id-type="pmid">19103769</pub-id><pub-id pub-id-type="doi">10.1128/IAI.00950-08</pub-id><pub-id pub-id-type="pmcid">PMC2643634</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siggins</surname><given-names>MK</given-names></name><name name-style="western"><surname>Sriskandan</surname><given-names>S</given-names></name></person-group><article-title>Bacterial Lymphatic Metastasis in Infection and Immunity</article-title><source>Cells</source><year>2022</year><volume>2022</volume><fpage>33</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells11010033</pub-id><pub-id pub-id-type="pmcid">PMC8750085</pub-id><pub-id pub-id-type="pmid">35011595</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Siggins, M. K. &amp; Sriskandan, S. Bacterial Lymphatic Metastasis in Infection and Immunity. <italic toggle="yes">Cells</italic><bold>2022</bold>, 33 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells11010033</pub-id><pub-id pub-id-type="pmcid">PMC8750085</pub-id><pub-id pub-id-type="pmid">35011595</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaaban</surname><given-names>T</given-names></name><name name-style="western"><surname>Mohsen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ezzeddine</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ghssein</surname><given-names>G</given-names></name></person-group><article-title>Overview of <italic toggle="yes">Yersinia pestis</italic> Metallophores: Yersiniabactin and Yersinopine</article-title><source>Biology</source><year>2023</year><volume>12</volume><fpage>598</fpage><pub-id pub-id-type="doi">10.3390/biology12040598</pub-id><pub-id pub-id-type="pmid">37106798</pub-id><pub-id pub-id-type="pmcid">PMC10136090</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Chaaban, T., Mohsen, Y., Ezzeddine, Z. &amp; Ghssein, G. Overview of <italic toggle="yes">Yersinia pestis</italic> Metallophores: Yersiniabactin and Yersinopine. <italic toggle="yes">Biology</italic><bold>12</bold>, 598 (2023).<pub-id pub-id-type="pmid">37106798</pub-id><pub-id pub-id-type="doi">10.3390/biology12040598</pub-id><pub-id pub-id-type="pmcid">PMC10136090</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul-Clark</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Differential effects of Gram-positive versus Gram-negative bacteria on NOSII and TNF in macrophages: role of TLRs in synergy between the two</article-title><source>Brit J. Pharm.</source><year>2006</year><volume>148</volume><fpage>1067</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706815</pub-id><pub-id pub-id-type="pmcid">PMC1752017</pub-id><pub-id pub-id-type="pmid">16783405</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Paul-Clark, M. J. et al. Differential effects of Gram-positive versus Gram-negative bacteria on NOSII and TNF in macrophages: role of TLRs in synergy between the two. <italic toggle="yes">Brit J. Pharm.</italic><bold>148</bold>, 1067&#8211;1075 (2006).<pub-id pub-id-type="doi">10.1038/sj.bjp.0706815</pub-id><pub-id pub-id-type="pmcid">PMC1752017</pub-id><pub-id pub-id-type="pmid">16783405</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><collab>Anon.</collab></person-group><article-title>Fatal Laboratory-Acquired Infection with an Attenuated <italic toggle="yes">Yersinia pestis</italic> Strain</article-title><source>Morbidity Mortal. Wkly. Rep. (MMWR)</source><year>2011</year><volume>60</volume><fpage>201</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">21346706</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Anon. Fatal Laboratory-Acquired Infection with an Attenuated <italic toggle="yes">Yersinia pestis</italic> Strain. <italic toggle="yes">Morbidity Mortal. Wkly. Rep. (MMWR)</italic><bold>60</bold>, 201&#8211;205 (2011).<pub-id pub-id-type="pmid">21346706</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawgood</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Haffkine</surname><given-names>WM</given-names></name></person-group><article-title>CIE (1860&#8211;1930): Prophylactic vaccination against cholera and bubonic plague in British India</article-title><source>J. Med. Biogr.</source><year>2007</year><volume>1</volume><fpage>9</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1258/j.jmb.2007.05-59</pub-id><pub-id pub-id-type="pmid">17356724</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Hawgood, B. J. &amp; Haffkine, W. M. CIE (1860&#8211;1930): Prophylactic vaccination against cholera and bubonic plague in British India. <italic toggle="yes">J. Med. Biogr.</italic><bold>1</bold>, 9&#8211;19 (2007).<pub-id pub-id-type="doi">10.1258/j.jmb.2007.05-59</pub-id><pub-id pub-id-type="pmid">17356724</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenzweig</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Progress on plague vaccine development</article-title><source>Appl Microbiol Biotechnol.</source><year>2011</year><volume>91</volume><fpage>265</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1007/s00253-011-3380-6</pub-id><pub-id pub-id-type="pmid">21670978</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Rosenzweig, J. A. et al. Progress on plague vaccine development. <italic toggle="yes">Appl Microbiol Biotechnol.</italic><bold>91</bold>, 265&#8211;286 (2011).<pub-id pub-id-type="pmid">21670978</pub-id><pub-id pub-id-type="doi">10.1007/s00253-011-3380-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feodorova</surname><given-names>VA</given-names></name><name name-style="western"><surname>Motin</surname><given-names>VL</given-names></name></person-group><article-title>Plague vaccines: current developments and future perspectives</article-title><source>Emerg. Microbes Infect.</source><year>2012</year><volume>1</volume><fpage>e36</fpage><pub-id pub-id-type="doi">10.1038/emi.2012.34</pub-id><pub-id pub-id-type="pmid">26038406</pub-id><pub-id pub-id-type="pmcid">PMC3630923</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Feodorova, V. A. &amp; Motin, V. L. Plague vaccines: current developments and future perspectives. <italic toggle="yes">Emerg. Microbes Infect.</italic><bold>1</bold>, e36 (2012).<pub-id pub-id-type="pmid">26038406</pub-id><pub-id pub-id-type="doi">10.1038/emi.2012.34</pub-id><pub-id pub-id-type="pmcid">PMC3630923</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenzweig</surname><given-names>JA</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>AK</given-names></name></person-group><article-title>The future of plague vaccines: hopes raised by a surrogate, live-attenuated recombinant vaccine candidate</article-title><source>Expert Rev. Vaccines.</source><year>2012</year><volume>11</volume><fpage>659</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1586/erv.12.34</pub-id><pub-id pub-id-type="pmid">22873124</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Rosenzweig, J. A. &amp; Chopra, A. K. The future of plague vaccines: hopes raised by a surrogate, live-attenuated recombinant vaccine candidate. <italic toggle="yes">Expert Rev. Vaccines.</italic><bold>11</bold>, 659&#8211;661 (2012).<pub-id pub-id-type="pmid">22873124</pub-id><pub-id pub-id-type="doi">10.1586/erv.12.34</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Feodorova V. A. et al. Russian vaccines against especially dangerous bacterial pathogens. <italic toggle="yes">Emerg Microbes Infect</italic>. <bold>3</bold>10.1038/emi.2014.82. (2014).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/emi.2014.82</pub-id><pub-id pub-id-type="pmcid">PMC4317636</pub-id><pub-id pub-id-type="pmid">26038506</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feodorova</surname><given-names>VA</given-names></name><name name-style="western"><surname>Sayapina</surname><given-names>LV</given-names></name><name name-style="western"><surname>Motin</surname><given-names>VL</given-names></name></person-group><article-title>Assessment of live plague vaccine candidates</article-title><source>Methods Mol. Biol.</source><year>2016</year><volume>1403</volume><fpage>487</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-3387-7_27</pub-id><pub-id pub-id-type="pmid">27076149</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Feodorova, V. A., Sayapina, L. V. &amp; Motin, V. L. Assessment of live plague vaccine candidates. <italic toggle="yes">Methods Mol. Biol.</italic><bold>1403</bold>, 487&#8211;498 (2016).<pub-id pub-id-type="pmid">27076149</pub-id><pub-id pub-id-type="doi">10.1007/978-1-4939-3387-7_27</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Verma S. K. and Tuteja U. Plague vaccine development: Current research and future trends. <italic toggle="yes">Frontiers in Immunology</italic><bold>7</bold>; 10.3389/fimmu.2016.00602 (2016).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2016.00602</pub-id><pub-id pub-id-type="pmcid">PMC5155008</pub-id><pub-id pub-id-type="pmid">28018363</pub-id></mixed-citation></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Singh</surname><given-names>AK</given-names></name></person-group><article-title>Plague vaccine: recent progress and prospects</article-title><source>NPJ Vaccines.</source><year>2019</year><volume>4</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1038/s41541-019-0105-9</pub-id><pub-id pub-id-type="pmid">30792905</pub-id><pub-id pub-id-type="pmcid">PMC6379378</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Sun, W. &amp; Singh, A. K. Plague vaccine: recent progress and prospects. <italic toggle="yes">NPJ Vaccines.</italic><bold>4</bold>, 11 (2019).<pub-id pub-id-type="pmid">30792905</pub-id><pub-id pub-id-type="doi">10.1038/s41541-019-0105-9</pub-id><pub-id pub-id-type="pmcid">PMC6379378</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenzweig</surname><given-names>JA</given-names></name><name name-style="western"><surname>Hendrix</surname><given-names>EK</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>AK</given-names></name></person-group><article-title>Plague vaccines: new developments in an ongoing search</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2021</year><volume>105</volume><fpage>4931</fpage><lpage>4941</lpage><pub-id pub-id-type="doi">10.1007/s00253-021-11389-6</pub-id><pub-id pub-id-type="pmid">34142207</pub-id><pub-id pub-id-type="pmcid">PMC8211537</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Rosenzweig, J. A., Hendrix, E. K. &amp; Chopra, A. K. Plague vaccines: new developments in an ongoing search. <italic toggle="yes">Appl. Microbiol. Biotechnol.</italic><bold>105</bold>, 4931&#8211;4941 (2021).<pub-id pub-id-type="pmid">34142207</pub-id><pub-id pub-id-type="doi">10.1007/s00253-021-11389-6</pub-id><pub-id pub-id-type="pmcid">PMC8211537</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">The Australian Immunisation Handbook, 8th edition, NHMRC, Australia. Australian Immunisation Handbook, 8th Edition Part 3: Vaccines Listed by Disease (wordpress.com) (2003).</mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sagiyev</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Human response to live plague vaccine EV, Almaty region, Kazakhstan, 2014&#8211;2015</article-title><source>PloS ONE</source><year>2019</year><volume>14</volume><fpage>e0218366</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0218366</pub-id><pub-id pub-id-type="pmid">31199832</pub-id><pub-id pub-id-type="pmcid">PMC6568420</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Sagiyev, Z. et al. Human response to live plague vaccine EV, Almaty region, Kazakhstan, 2014&#8211;2015. <italic toggle="yes">PloS ONE</italic><bold>14</bold>, e0218366 (2019).<pub-id pub-id-type="pmid">31199832</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0218366</pub-id><pub-id pub-id-type="pmcid">PMC6568420</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feodorova</surname><given-names>VA</given-names></name><name name-style="western"><surname>Corbel</surname><given-names>MJ</given-names></name></person-group><article-title>Prospects for new plague vaccines</article-title><source>Expert Rev. Vaccines.</source><year>2009</year><volume>8</volume><fpage>1721</fpage><lpage>1738</lpage><pub-id pub-id-type="doi">10.1586/erv.09.129</pub-id><pub-id pub-id-type="pmid">19943765</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Feodorova, V. A. &amp; Corbel, M. J. Prospects for new plague vaccines. <italic toggle="yes">Expert Rev. Vaccines.</italic><bold>8</bold>, 1721&#8211;1738 (2009).<pub-id pub-id-type="pmid">19943765</pub-id><pub-id pub-id-type="doi">10.1586/erv.09.129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilgore</surname><given-names>PB</given-names></name><etal/></person-group><article-title>Combinatorial viral vector-based and live attenuated vaccines without an adjuvant to generate broader immune responses to effectively combat pneumonic plague</article-title><source>mBio</source><year>2021</year><volume>12</volume><fpage>e03223</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1128/mBio.03223-21</pub-id><pub-id pub-id-type="pmid">34872353</pub-id><pub-id pub-id-type="pmcid">PMC8649767</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Kilgore, P. B. et al. Combinatorial viral vector-based and live attenuated vaccines without an adjuvant to generate broader immune responses to effectively combat pneumonic plague. <italic toggle="yes">mBio</italic><bold>12</bold>, e03223&#8211;21 (2021).<pub-id pub-id-type="pmid">34872353</pub-id><pub-id pub-id-type="doi">10.1128/mBio.03223-21</pub-id><pub-id pub-id-type="pmcid">PMC8649767</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quenee</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Hereditary Hemochromatosis Restores the Virulence of Plague Vaccine Strains</article-title><source>J. Infect. Dis.</source><year>2012</year><volume>206</volume><fpage>1050</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis433</pub-id><pub-id pub-id-type="pmid">22896664</pub-id><pub-id pub-id-type="pmcid">PMC3501692</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Quenee, L. E. et al. Hereditary Hemochromatosis Restores the Virulence of Plague Vaccine Strains. <italic toggle="yes">J. Infect. Dis.</italic><bold>206</bold>, 1050&#8211;1058 (2012).<pub-id pub-id-type="pmid">22896664</pub-id><pub-id pub-id-type="doi">10.1093/infdis/jis433</pub-id><pub-id pub-id-type="pmcid">PMC3501692</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bacon</surname><given-names>GA</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>TW</given-names></name></person-group><article-title>The basis of virulence in Pasteurella pestis: an antigen determining virulence</article-title><source>Br. J. Exp. Pathol.</source><year>1956</year><volume>37</volume><fpage>481</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">13374206</pub-id><pub-id pub-id-type="pmcid">PMC2083499</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Bacon, G. A. &amp; Burrows, T. W. The basis of virulence in Pasteurella pestis: an antigen determining virulence. <italic toggle="yes">Br. J. Exp. Pathol.</italic><bold>37</bold>, 481&#8211;493 (1956).<pub-id pub-id-type="pmid">13374206</pub-id><pub-id pub-id-type="pmcid">PMC2083499</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>ED</given-names></name><etal/></person-group><article-title>A new improved sub-unit vaccine for plague: the basis of protection</article-title><source>FEMS Immunol. Med Microbiol.</source><year>1995</year><volume>12</volume><fpage>223</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.1995.tb00196.x</pub-id><pub-id pub-id-type="pmid">8745007</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Williamson, E. D. et al. A new improved sub-unit vaccine for plague: the basis of protection. <italic toggle="yes">FEMS Immunol. Med Microbiol.</italic><bold>12</bold>, 223&#8211;230 (1995).<pub-id pub-id-type="pmid">8745007</pub-id><pub-id pub-id-type="doi">10.1111/j.1574-695X.1995.tb00196.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heath</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine</article-title><source>Vaccine</source><year>1998</year><volume>16</volume><fpage>1131</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(98)80110-2</pub-id><pub-id pub-id-type="pmid">9682370</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Heath, D. G. et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. <italic toggle="yes">Vaccine</italic><bold>16</bold>, 1131&#8211;1137 (1998).<pub-id pub-id-type="pmid">9682370</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(98)80110-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>ED</given-names></name><etal/></person-group><article-title>Kinetics of the immune response to the (F1&#8201;+&#8201;V) vaccine in models of bubonic and pneumonic plague</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>1142</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.09.052</pub-id><pub-id pub-id-type="pmid">17101198</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Williamson, E. D. et al. Kinetics of the immune response to the (F1&#8201;+&#8201;V) vaccine in models of bubonic and pneumonic plague. <italic toggle="yes">Vaccine</italic><bold>25</bold>, 1142&#8211;1148 (2007).<pub-id pub-id-type="pmid">17101198</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.09.052</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quenee</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Plague in Guinea pigs and its prevention by subunit vaccines</article-title><source>Am. J. Pathol.</source><year>2011</year><volume>178</volume><fpage>1689</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2010.12.028</pub-id><pub-id pub-id-type="pmid">21406168</pub-id><pub-id pub-id-type="pmcid">PMC3078462</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Quenee, L. E. et al. Plague in Guinea pigs and its prevention by subunit vaccines. <italic toggle="yes">Am. J. Pathol.</italic><bold>178</bold>, 1689&#8211;1700 (2011).<pub-id pub-id-type="pmid">21406168</pub-id><pub-id pub-id-type="doi">10.1016/j.ajpath.2010.12.028</pub-id><pub-id pub-id-type="pmcid">PMC3078462</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demeure</surname><given-names>CE</given-names></name><etal/></person-group><article-title><italic toggle="yes">Yersinia pestis</italic> and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics</article-title><source>Genes Immun.</source><year>2019</year><volume>20</volume><fpage>357</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1038/s41435-019-0065-0</pub-id><pub-id pub-id-type="pmid">30940874</pub-id><pub-id pub-id-type="pmcid">PMC6760536</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Demeure, C. E. et al. <italic toggle="yes">Yersinia pestis</italic> and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics. <italic toggle="yes">Genes Immun.</italic><bold>20</bold>, 357&#8211;370 (2019).<pub-id pub-id-type="pmid">30940874</pub-id><pub-id pub-id-type="doi">10.1038/s41435-019-0065-0</pub-id><pub-id pub-id-type="pmcid">PMC6760536</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="other">Erova T. E. et al. Evaluation of Protective Potential of <italic toggle="yes">Yersinia pestis</italic> Outer Membrane Protein Antigens as Possible Candidates for a New-Generation Recombinant Plague Vaccine. <italic toggle="yes">Clin. Vaccine Immunol.</italic><bold>20</bold>10.1128/CVI.00597-12 (2013).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CVI.00597-12</pub-id><pub-id pub-id-type="pmcid">PMC3571283</pub-id><pub-id pub-id-type="pmid">23239803</pub-id></mixed-citation></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matson</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Immunization of mice with YscF provides protection from <italic toggle="yes">Yersinia pestis</italic> infections</article-title><source>BMC Microbiol.</source><year>2005</year><volume>5</volume><fpage>38</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1186/1471-2180-5-38</pub-id><pub-id pub-id-type="pmid">15978133</pub-id><pub-id pub-id-type="pmcid">PMC1168899</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Matson, J. S. et al. Immunization of mice with YscF provides protection from <italic toggle="yes">Yersinia pestis</italic> infections. <italic toggle="yes">BMC Microbiol.</italic><bold>5</bold>, 38&#8211;55 (2005).<pub-id pub-id-type="pmid">15978133</pub-id><pub-id pub-id-type="doi">10.1186/1471-2180-5-38</pub-id><pub-id pub-id-type="pmcid">PMC1168899</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">Ivanov M. I. et al.. Vaccination of Mice with a Yop Translocon Complex Elicits Antibodies That Are Protective against Infection with F1&#8722;Yersinia pestis. <italic toggle="yes">Infect Immun</italic><bold>76</bold>10.1128/iai.00189-08 (2008).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.00189-08</pub-id><pub-id pub-id-type="pmcid">PMC2573372</pub-id><pub-id pub-id-type="pmid">18765742</pub-id></mixed-citation></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swietncki</surname><given-names>W</given-names></name><name name-style="western"><surname>Powell</surname><given-names>BS</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>J</given-names></name></person-group><article-title><italic toggle="yes">Yersinia pestis</italic> Yop secretion protein F: purification, characterization and protective efficacy against bubonic plague</article-title><source>Protein Expr. Purif.</source><year>2005</year><volume>42</volume><fpage>166</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2005.02.016</pub-id><pub-id pub-id-type="pmid">15939303</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Swietncki, W., Powell, B. S. &amp; Goodwin, J. <italic toggle="yes">Yersinia pestis</italic> Yop secretion protein F: purification, characterization and protective efficacy against bubonic plague. <italic toggle="yes">Protein Expr. Purif.</italic><bold>42</bold>, 166&#8211;172 (2005).<pub-id pub-id-type="pmid">15939303</pub-id><pub-id pub-id-type="doi">10.1016/j.pep.2005.02.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>ED</given-names></name><etal/></person-group><article-title>Recombinant (F1&#8201;+&#8201;V) vaccine protects cynomolgus macaques against pneumonic plague</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>4771</fpage><lpage>4777</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.04.084</pub-id><pub-id pub-id-type="pmid">21570437</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Williamson, E. D. et al. Recombinant (F1&#8201;+&#8201;V) vaccine protects cynomolgus macaques against pneumonic plague. <italic toggle="yes">Vaccine</italic><bold>29</bold>, 4771&#8211;4777 (2011).<pub-id pub-id-type="pmid">21570437</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.04.084</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fellows</surname><given-names>P</given-names></name><etal/></person-group><article-title>Characterization of a cynomolgus macaque model of pneumonic plague for evaluation of vaccine efficacy</article-title><source>Clin. Vaccin. Immunol.</source><year>2015</year><volume>22</volume><fpage>1070</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1128/CVI.00290-15</pub-id><pub-id pub-id-type="pmcid">PMC4550665</pub-id><pub-id pub-id-type="pmid">26224691</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Fellows, P. et al. Characterization of a cynomolgus macaque model of pneumonic plague for evaluation of vaccine efficacy. <italic toggle="yes">Clin. Vaccin. Immunol.</italic><bold>22</bold>, 1070&#8211;1078 (2015).<pub-id pub-id-type="doi">10.1128/CVI.00290-15</pub-id><pub-id pub-id-type="pmcid">PMC4550665</pub-id><pub-id pub-id-type="pmid">26224691</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fellows</surname><given-names>P</given-names></name><etal/></person-group><article-title>Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>7748</fpage><lpage>7756</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.09.062</pub-id><pub-id pub-id-type="pmid">20920572</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Fellows, P. et al. Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V). <italic toggle="yes">Vaccine</italic><bold>28</bold>, 7748&#8211;7756 (2010).<pub-id pub-id-type="pmid">20920572</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.09.062</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quenee</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>6572</fpage><lpage>6583</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.119</pub-id><pub-id pub-id-type="pmid">21763383</pub-id><pub-id pub-id-type="pmcid">PMC3538834</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Quenee, L. E. et al. Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines. <italic toggle="yes">Vaccine</italic><bold>29</bold>, 6572&#8211;6583 (2011).<pub-id pub-id-type="pmid">21763383</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.119</pub-id><pub-id pub-id-type="pmcid">PMC3538834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aftalion</surname><given-names>M</given-names></name><etal/></person-group><article-title>Rapid induction of protective immunity against pneumonic plague by <italic toggle="yes">Yersinia pestis</italic> Polymeric F1 and LcrV Antigens</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>581</fpage><pub-id pub-id-type="doi">10.3390/vaccines11030581</pub-id><pub-id pub-id-type="pmid">36992165</pub-id><pub-id pub-id-type="pmcid">PMC10054699</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Aftalion, M. et al. Rapid induction of protective immunity against pneumonic plague by <italic toggle="yes">Yersinia pestis</italic> Polymeric F1 and LcrV Antigens. <italic toggle="yes">Vaccines</italic><bold>11</bold>, 581 (2023).<pub-id pub-id-type="pmid">36992165</pub-id><pub-id pub-id-type="doi">10.3390/vaccines11030581</pub-id><pub-id pub-id-type="pmcid">PMC10054699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>T</given-names></name><etal/></person-group><article-title>Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection</article-title><source>Vaccine</source><year>2006</year><volume>6</volume><fpage>1625</fpage><lpage>1632</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.09.052</pub-id><pub-id pub-id-type="pmid">16243411</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Jones, T. et al. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. <italic toggle="yes">Vaccine</italic><bold>6</bold>, 1625&#8211;1632 (2006).<pub-id pub-id-type="doi">10.1016/j.vaccine.2005.09.052</pub-id><pub-id pub-id-type="pmid">16243411</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honko</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis</article-title><source>Infect. Immun.</source><year>2006</year><volume>74</volume><fpage>1113</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1128/IAI.74.2.1113-1120.2006</pub-id><pub-id pub-id-type="pmid">16428759</pub-id><pub-id pub-id-type="pmcid">PMC1360354</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Honko, A. N. et al. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. <italic toggle="yes">Infect. Immun.</italic><bold>74</bold>, 1113&#8211;1120 (2006).<pub-id pub-id-type="pmid">16428759</pub-id><pub-id pub-id-type="doi">10.1128/IAI.74.2.1113-1120.2006</pub-id><pub-id pub-id-type="pmcid">PMC1360354</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mizel</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates</article-title><source>Clin. Vaccin. Immunol.</source><year>2009</year><volume>16</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1128/CVI.00333-08</pub-id><pub-id pub-id-type="pmcid">PMC2620661</pub-id><pub-id pub-id-type="pmid">18987167</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Mizel, S. B. et al. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. <italic toggle="yes">Clin. Vaccin. Immunol.</italic><bold>16</bold>, 21&#8211;28 (2009).<pub-id pub-id-type="doi">10.1128/CVI.00333-08</pub-id><pub-id pub-id-type="pmcid">PMC2620661</pub-id><pub-id pub-id-type="pmid">18987167</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague</article-title><source>Acta Biomater.</source><year>2019</year><volume>100</volume><fpage>326</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2019.10.016</pub-id><pub-id pub-id-type="pmid">31610342</pub-id><pub-id pub-id-type="pmcid">PMC7012387</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Wagner, D. A. et al. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague. <italic toggle="yes">Acta Biomater.</italic><bold>100</bold>, 326&#8211;337 (2019).<pub-id pub-id-type="pmid">31610342</pub-id><pub-id pub-id-type="doi">10.1016/j.actbio.2019.10.016</pub-id><pub-id pub-id-type="pmcid">PMC7012387</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>XO</given-names></name><etal/></person-group><article-title>Manganese-based nanoparticle vaccine for combating fatal bacterial pneumonia</article-title><source>Adv. Mater.</source><year>2023</year><volume>35</volume><fpage>2304514</fpage><pub-id pub-id-type="doi">10.1002/adma.202304514</pub-id><pub-id pub-id-type="pmid">37784226</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Yang, X. O. et al. Manganese-based nanoparticle vaccine for combating fatal bacterial pneumonia. <italic toggle="yes">Adv. Mater.</italic><bold>35</bold>, 2304514 (2023).<pub-id pub-id-type="doi">10.1002/adma.202304514</pub-id><pub-id pub-id-type="pmid">37784226</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dentovskaya</surname><given-names>SV</given-names></name><etal/></person-group><article-title>Peptidoglycan-Free Bacterial Ghosts Confer Enhanced Protection against <italic toggle="yes">Yersinia pestis</italic> Infection</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.3390/vaccines10010051</pub-id><pub-id pub-id-type="pmcid">PMC8777944</pub-id><pub-id pub-id-type="pmid">35062712</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Dentovskaya, S. V. et al. Peptidoglycan-Free Bacterial Ghosts Confer Enhanced Protection against <italic toggle="yes">Yersinia pestis</italic> Infection. <italic toggle="yes">Vaccines</italic><bold>10</bold>, 51 (2022).<pub-id pub-id-type="doi">10.3390/vaccines10010051</pub-id><pub-id pub-id-type="pmcid">PMC8777944</pub-id><pub-id pub-id-type="pmid">35062712</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>GWJ</given-names></name><etal/></person-group><article-title>Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis</article-title><source>Infect. Immun.</source><year>1996</year><volume>64</volume><fpage>4580</fpage><lpage>4585</lpage><pub-id pub-id-type="doi">10.1128/iai.64.11.4580-4585.1996</pub-id><pub-id pub-id-type="pmid">8890210</pub-id><pub-id pub-id-type="pmcid">PMC174416</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Anderson, G. W. J. et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. <italic toggle="yes">Infect. Immun.</italic><bold>64</bold>, 4580&#8211;4585 (1996).<pub-id pub-id-type="pmid">8890210</pub-id><pub-id pub-id-type="doi">10.1128/iai.64.11.4580-4585.1996</pub-id><pub-id pub-id-type="pmcid">PMC174416</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>A</given-names></name><etal/></person-group><article-title>Use of Bioengineered Human Commensal Gut Bacteria-Derived Microvesicles for Mucosal Plague Vaccine Delivery and Immunization</article-title><source>Clin. Exp. Immunol.</source><year>2019</year><volume>196</volume><fpage>287</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1111/cei.13301</pub-id><pub-id pub-id-type="pmid">30985006</pub-id><pub-id pub-id-type="pmcid">PMC6514708</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Carvalho, A. et al. Use of Bioengineered Human Commensal Gut Bacteria-Derived Microvesicles for Mucosal Plague Vaccine Delivery and Immunization. <italic toggle="yes">Clin. Exp. Immunol.</italic><bold>196</bold>, 287&#8211;304 (2019).<pub-id pub-id-type="pmid">30985006</pub-id><pub-id pub-id-type="doi">10.1111/cei.13301</pub-id><pub-id pub-id-type="pmcid">PMC6514708</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byvalov</surname><given-names>AA</given-names></name><name name-style="western"><surname>Konyshev</surname><given-names>IV</given-names></name><name name-style="western"><surname>Uversky</surname><given-names>VN</given-names></name><name name-style="western"><surname>Dentovskaya</surname><given-names>SV</given-names></name><name name-style="western"><surname>Anisimov</surname><given-names>AP</given-names></name></person-group><article-title>Yersinia Outer Membrane Vesicles as Potential Vaccine Candidates in Protecting against Plague</article-title><source>Biomolecules</source><year>2020</year><volume>10</volume><fpage>1694</fpage><pub-id pub-id-type="doi">10.3390/biom10121694</pub-id><pub-id pub-id-type="pmid">33353123</pub-id><pub-id pub-id-type="pmcid">PMC7766529</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Byvalov, A. A., Konyshev, I. V., Uversky, V. N., Dentovskaya, S. V. &amp; Anisimov, A. P. Yersinia Outer Membrane Vesicles as Potential Vaccine Candidates in Protecting against Plague. <italic toggle="yes">Biomolecules</italic><bold>10</bold>, 1694 (2020).<pub-id pub-id-type="pmid">33353123</pub-id><pub-id pub-id-type="doi">10.3390/biom10121694</pub-id><pub-id pub-id-type="pmcid">PMC7766529</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>BD</given-names></name><etal/></person-group><article-title>Predictors of survival after vaccination in a pneumonic plague model</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><fpage>145</fpage><pub-id pub-id-type="doi">10.3390/vaccines10020145</pub-id><pub-id pub-id-type="pmid">35214604</pub-id><pub-id pub-id-type="pmcid">PMC8876284</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Moore, B. D. et al. Predictors of survival after vaccination in a pneumonic plague model. <italic toggle="yes">Vaccines</italic><bold>10</bold>, 145 (2022).<pub-id pub-id-type="pmid">35214604</pub-id><pub-id pub-id-type="doi">10.3390/vaccines10020145</pub-id><pub-id pub-id-type="pmcid">PMC8876284</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Targeting of the Yersinia pestis F1 capsular antigen by innate-like B1b cells mediates a rapid protective response against bubonic plague</article-title><source>NPJ Vaccines</source><year>2018</year><volume>3</volume><fpage>52</fpage><pub-id pub-id-type="doi">10.1038/s41541-018-0087-z</pub-id><pub-id pub-id-type="pmid">30374415</pub-id><pub-id pub-id-type="pmcid">PMC6195588</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Levy, Y. et al. Targeting of the Yersinia pestis F1 capsular antigen by innate-like B1b cells mediates a rapid protective response against bubonic plague. <italic toggle="yes">NPJ Vaccines</italic><bold>3</bold>, 52 (2018).<pub-id pub-id-type="pmid">30374415</pub-id><pub-id pub-id-type="doi">10.1038/s41541-018-0087-z</pub-id><pub-id pub-id-type="pmcid">PMC6195588</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goncharova</surname><given-names>A</given-names></name><etal/></person-group><article-title>Assessment of the effect of using immunomodulatory drugs for emergency prevention of experimental plague caused by a virulent strain of the main subspecies <italic toggle="yes">Yersinia pestis</italic></article-title><source>J. Microbiol., Epidemiol. Immunobiol.</source><year>2024</year><volume>101</volume><fpage>2024</fpage><pub-id pub-id-type="doi">10.36233/0372-9311-415</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Goncharova, A. et al. Assessment of the effect of using immunomodulatory drugs for emergency prevention of experimental plague caused by a virulent strain of the main subspecies <italic toggle="yes">Yersinia pestis</italic>. <italic toggle="yes">J. Microbiol., Epidemiol. Immunobiol.</italic><bold>101</bold>, 2024 (2024).<pub-id pub-id-type="doi">10.36233/0372-9311-415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galloway</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Co-formulation of the rF1V plague vaccine with depot-formulated cytokines enhances immunogenicity and efficacy to elicit protective responses against aerosol challenge in mice</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><fpage>1277526</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2024.1277526</pub-id><pub-id pub-id-type="pmid">38605961</pub-id><pub-id pub-id-type="pmcid">PMC11007139</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Galloway, D. R. et al. Co-formulation of the rF1V plague vaccine with depot-formulated cytokines enhances immunogenicity and efficacy to elicit protective responses against aerosol challenge in mice. <italic toggle="yes">Front. Immunol.</italic><bold>15</bold>, 1277526 (2024).<pub-id pub-id-type="pmid">38605961</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1277526</pub-id><pub-id pub-id-type="pmcid">PMC11007139</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><mixed-citation publication-type="other">Marketing authorisation from the State Research Centre for Applied Microbiology amnd Biotechnology of the Federal Service for the Supervision of Consumer Rights and Protection (Russia); Registration LP-004808 Microencapsulated molecular plague vaccine (PMMM, 2024) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.rlsnet.ru/regdoc/vakcina-cumnaya-molekulyarnaya-mikroinkapsulirovannaya-vcmm-lp-004808-74621">https://www.rlsnet.ru/regdoc/vakcina-cumnaya-molekulyarnaya-mikroinkapsulirovannaya-vcmm-lp-004808-74621</ext-link>.</mixed-citation></ref><ref id="CR87"><label>87.</label><mixed-citation publication-type="other">Goncharova, A. et al. Experimental Evaluation of Application of the Vaccine Strain Yersinia pestis EV NIIEG in Combination with Immune-Modulators. <italic toggle="yes">Problems of Particularly Dangerous Infections</italic>. 71-77. 10.21055/0370-1069-2020-2-71-77. (2020).</mixed-citation></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiner</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Immunisation of two rodent species with new live-attenuated mutants of <italic toggle="yes">Yersinia pestis</italic> CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague</article-title><source>NPJ Vaccines.</source><year>2016</year><volume>1</volume><fpage>16020</fpage><pub-id pub-id-type="doi">10.1038/npjvaccines.2016.20</pub-id><pub-id pub-id-type="pmid">29263858</pub-id><pub-id pub-id-type="pmcid">PMC5707884</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Tiner, B. L. et al. Immunisation of two rodent species with new live-attenuated mutants of <italic toggle="yes">Yersinia pestis</italic> CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague. <italic toggle="yes">NPJ Vaccines.</italic><bold>1</bold>, 16020 (2016).<pub-id pub-id-type="pmid">29263858</pub-id><pub-id pub-id-type="doi">10.1038/npjvaccines.2016.20</pub-id><pub-id pub-id-type="pmcid">PMC5707884</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiner</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Combinational deletion of three membrane protein-encoding genes highly attenuates yersinia pestis while retaining immunogenicity in a mouse model of pneumonic plague</article-title><source>Infect. Immun.</source><year>2015</year><volume>83</volume><fpage>1318</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1128/IAI.02778-14</pub-id><pub-id pub-id-type="pmid">25605764</pub-id><pub-id pub-id-type="pmcid">PMC4363438</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Tiner, B. L. et al. Combinational deletion of three membrane protein-encoding genes highly attenuates yersinia pestis while retaining immunogenicity in a mouse model of pneumonic plague. <italic toggle="yes">Infect. Immun.</italic><bold>83</bold>, 1318&#8211;1338 (2015A).<pub-id pub-id-type="pmid">25605764</pub-id><pub-id pub-id-type="doi">10.1128/IAI.02778-14</pub-id><pub-id pub-id-type="pmcid">PMC4363438</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiner</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of <italic toggle="yes">Yersinia pestis</italic> CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague</article-title><source>Clin. Vaccin. Immunol.</source><year>2015</year><volume>22</volume><fpage>1255</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1128/CVI.00499-15</pub-id><pub-id pub-id-type="pmcid">PMC4658590</pub-id><pub-id pub-id-type="pmid">26446423</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Tiner, B. L. et al. Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of <italic toggle="yes">Yersinia pestis</italic> CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague. <italic toggle="yes">Clin. Vaccin. Immunol.</italic><bold>22</bold>, 1255&#8211;1268 (2015B).<pub-id pub-id-type="doi">10.1128/CVI.00499-15</pub-id><pub-id pub-id-type="pmcid">PMC4658590</pub-id><pub-id pub-id-type="pmid">26446423</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Lier</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Deletion of Braun lipoprotein and plasminogen-activating protease-encoding genes attenuates <italic toggle="yes">Yersinia pestis</italic> in mouse models of bubonic and pneumonic plague</article-title><source>Infect. Immun.</source><year>2014</year><volume>82</volume><fpage>2485</fpage><lpage>2503</lpage><pub-id pub-id-type="doi">10.1128/IAI.01595-13</pub-id><pub-id pub-id-type="pmid">24686064</pub-id><pub-id pub-id-type="pmcid">PMC4019162</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Van Lier, C. J. et al. Deletion of Braun lipoprotein and plasminogen-activating protease-encoding genes attenuates <italic toggle="yes">Yersinia pestis</italic> in mouse models of bubonic and pneumonic plague. <italic toggle="yes">Infect. Immun.</italic><bold>82</bold>, 2485&#8211;2503 (2014).<pub-id pub-id-type="pmid">24686064</pub-id><pub-id pub-id-type="doi">10.1128/IAI.01595-13</pub-id><pub-id pub-id-type="pmcid">PMC4019162</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><mixed-citation publication-type="other">Junxia F. et al. Construction of a Live-Attenuated Vaccine Strain of <italic toggle="yes">Yersinia pestis</italic> EV76-B-SHU&#916;pla and Evaluation of Its Protection Efficacy in a Mouse Model by Aerosolized Intratracheal Inoculation.<italic toggle="yes">Cell. Infect. Microbiol</italic>.,<bold>10</bold>10.3389/fcimb.2020.00473 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2020.00473</pub-id><pub-id pub-id-type="pmcid">PMC7509399</pub-id><pub-id pub-id-type="pmid">33014895</pub-id></mixed-citation></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cote</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Protection Elicited by Attenuated Live <italic toggle="yes">Yersinia pestis</italic> Vaccine Strains against Lethal Infection with Virulent <italic toggle="yes">Y. pestis</italic></article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>161</fpage><pub-id pub-id-type="doi">10.3390/vaccines9020161</pub-id><pub-id pub-id-type="pmid">33669472</pub-id><pub-id pub-id-type="pmcid">PMC7920443</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Cote, C. K. et al. Protection Elicited by Attenuated Live <italic toggle="yes">Yersinia pestis</italic> Vaccine Strains against Lethal Infection with Virulent <italic toggle="yes">Y. pestis</italic>. <italic toggle="yes">Vaccines</italic><bold>9</bold>, 161 (2021).<pub-id pub-id-type="pmid">33669472</pub-id><pub-id pub-id-type="doi">10.3390/vaccines9020161</pub-id><pub-id pub-id-type="pmcid">PMC7920443</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><mixed-citation publication-type="other">WHO R&amp;D blueprint: Plague vaccines workshop <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/blueprint/what/norms-standards/Plague_vaccines_workshop-23-april-2018/en/">https://www.who.int/blueprint/what/norms-standards/Plague_vaccines_workshop-23-april-2018/en/</ext-link> (2018).</mixed-citation></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demeure</surname><given-names>C</given-names></name><etal/></person-group><article-title><italic toggle="yes">Yersinia pestis</italic> and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination and diagnostics</article-title><source>Microbes Infect.</source><year>2019</year><volume>21</volume><fpage>202</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2019.06.007</pub-id><pub-id pub-id-type="pmid">31252217</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Demeure, C. et al. <italic toggle="yes">Yersinia pestis</italic> and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination and diagnostics. <italic toggle="yes">Microbes Infect.</italic><bold>21</bold>, 202&#8211;212 (2019).<pub-id pub-id-type="pmid">31252217</pub-id><pub-id pub-id-type="doi">10.1016/j.micinf.2019.06.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dentovskaya</surname><given-names>SV</given-names></name><etal/></person-group><article-title>Molecular bases of vaccine-prevention of plague</article-title><source>Mol. Genet. Microbiol. Virol.</source><year>2013</year><volume>28</volume><fpage>87</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.3103/S089141681303004X</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Dentovskaya, S. V. et al. Molecular bases of vaccine-prevention of plague. <italic toggle="yes">Mol. Genet. Microbiol. Virol.</italic><bold>28</bold>, 87&#8211;98 (2013).<pub-id pub-id-type="doi">10.3103/S089141681303004X</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersson</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Identification of New Virulence Factors and Vaccine Candidates for <italic toggle="yes">Yersinia pestis</italic></article-title><source>Front Cell Infect. Microbiol.</source><year>2017</year><volume>7</volume><fpage>448</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2017.00448</pub-id><pub-id pub-id-type="pmid">29090192</pub-id><pub-id pub-id-type="pmcid">PMC5650977</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Andersson, J. A. et al. Identification of New Virulence Factors and Vaccine Candidates for <italic toggle="yes">Yersinia pestis</italic>. <italic toggle="yes">Front Cell Infect. Microbiol.</italic><bold>7</bold>, 448 (2017).<pub-id pub-id-type="pmid">29090192</pub-id><pub-id pub-id-type="doi">10.3389/fcimb.2017.00448</pub-id><pub-id pub-id-type="pmcid">PMC5650977</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R</given-names></name></person-group><article-title>Live-attenuated <italic toggle="yes">Yersinia pestis</italic> vaccines</article-title><source>Expert Rev. Vaccines.</source><year>2013</year><volume>12</volume><fpage>677</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1586/erv.13.42</pub-id><pub-id pub-id-type="pmid">23750796</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Wang, X., Zhang, X., Zhou, D. &amp; Yang, R. Live-attenuated <italic toggle="yes">Yersinia pestis</italic> vaccines. <italic toggle="yes">Expert Rev. Vaccines.</italic><bold>12</bold>, 677&#8211;686 (2013).<pub-id pub-id-type="pmid">23750796</pub-id><pub-id pub-id-type="doi">10.1586/erv.13.42</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humphreys</surname><given-names>IR</given-names></name><name name-style="western"><surname>Sebastian</surname><given-names>S</given-names></name></person-group><article-title>Novel viral vectors in infectious diseases</article-title><source>Immunology</source><year>2018</year><volume>153</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/imm.12829</pub-id><pub-id pub-id-type="pmid">28869761</pub-id><pub-id pub-id-type="pmcid">PMC5721250</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Humphreys, I. R. &amp; Sebastian, S. Novel viral vectors in infectious diseases. <italic toggle="yes">Immunology</italic><bold>153</bold>, 1&#8211;9 (2018).<pub-id pub-id-type="pmid">28869761</pub-id><pub-id pub-id-type="doi">10.1111/imm.12829</pub-id><pub-id pub-id-type="pmcid">PMC5721250</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases</article-title><source>Sig Transduct. Target Ther.</source><year>2023</year><volume>8</volume><fpage>149</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01408-5</pub-id><pub-id pub-id-type="pmcid">PMC10081433</pub-id><pub-id pub-id-type="pmid">37029123</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Wang, S. et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. <italic toggle="yes">Sig Transduct. Target Ther.</italic><bold>8</bold>, 149 (2023).<pub-id pub-id-type="doi">10.1038/s41392-023-01408-5</pub-id><pub-id pub-id-type="pmcid">PMC10081433</pub-id><pub-id pub-id-type="pmid">37029123</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derbise</surname><given-names>A</given-names></name><etal/></person-group><article-title>An encapsulated <italic toggle="yes">Yersinia pseudotuberculosis</italic> is a highly efficient vaccine against pneumonic plague</article-title><source>PLoS Negl. Trop. Dis.</source><year>2012</year><volume>6</volume><fpage>e1528</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0001528</pub-id><pub-id pub-id-type="pmid">22348169</pub-id><pub-id pub-id-type="pmcid">PMC3279354</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Derbise, A. et al. An encapsulated <italic toggle="yes">Yersinia pseudotuberculosis</italic> is a highly efficient vaccine against pneumonic plague. <italic toggle="yes">PLoS Negl. Trop. Dis.</italic><bold>6</bold>, e1528 (2012).<pub-id pub-id-type="pmid">22348169</pub-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0001528</pub-id><pub-id pub-id-type="pmcid">PMC3279354</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><mixed-citation publication-type="other">Derbise A., et al. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination. <italic toggle="yes">PLoS Negl Trop Dis</italic>. <bold>16</bold>10.1371/journal.pntd.0004162 (2015).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0004162</pub-id><pub-id pub-id-type="pmcid">PMC4608741</pub-id><pub-id pub-id-type="pmid">26473734</pub-id></mixed-citation></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demeure</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine</article-title><source>Vaccine</source><year>2019</year><volume>3</volume><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.11.022</pub-id><pub-id pub-id-type="pmid">30467064</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Demeure, C. E. et al. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine. <italic toggle="yes">Vaccine</italic><bold>3</bold>, 123&#8211;129 (2019).<pub-id pub-id-type="doi">10.1016/j.vaccine.2018.11.022</pub-id><pub-id pub-id-type="pmid">30467064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derbise</surname><given-names>A</given-names></name><etal/></person-group><article-title>Subcutaneous vaccination with a live attenuated <italic toggle="yes">Yersinia pseudotuberculosis</italic> plague vaccine</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>1888</fpage><lpage>1892</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.01.014</pub-id><pub-id pub-id-type="pmid">31964555</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Derbise, A. et al. Subcutaneous vaccination with a live attenuated <italic toggle="yes">Yersinia pseudotuberculosis</italic> plague vaccine. <italic toggle="yes">Vaccine</italic><bold>38</bold>, 1888&#8211;1892 (2020).<pub-id pub-id-type="pmid">31964555</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.01.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Remodeling <italic toggle="yes">Yersinia pseudotuberculosis</italic> to generate a highly immunogenic outer membrane vesicle vaccine against pneumonic plague</article-title><source>PNAS</source><year>2022</year><volume>119</volume><fpage>e2109667119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2109667119</pub-id><pub-id pub-id-type="pmid">35275791</pub-id><pub-id pub-id-type="pmcid">PMC8931243</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Wang, X. et al. Remodeling <italic toggle="yes">Yersinia pseudotuberculosis</italic> to generate a highly immunogenic outer membrane vesicle vaccine against pneumonic plague. <italic toggle="yes">PNAS</italic><bold>119</bold>, e2109667119 (2022).<pub-id pub-id-type="pmid">35275791</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2109667119</pub-id><pub-id pub-id-type="pmcid">PMC8931243</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morton</surname><given-names>M</given-names></name><etal/></person-group><article-title>A <italic toggle="yes">Salmonella enterica</italic> serovar Typhi vaccine expressing <italic toggle="yes">Yersinia pestis</italic> F1 antigen on its surface provides protection against plague in mice</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>2524</fpage><lpage>2532</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.01.007</pub-id><pub-id pub-id-type="pmid">15193377</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Morton, M. et al. A <italic toggle="yes">Salmonella enterica</italic> serovar Typhi vaccine expressing <italic toggle="yes">Yersinia pestis</italic> F1 antigen on its surface provides protection against plague in mice. <italic toggle="yes">Vaccine</italic><bold>22</bold>, 2524&#8211;2532 (2004).<pub-id pub-id-type="pmid">15193377</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.01.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garmory</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live <italic toggle="yes">Salmonella enterica</italic> Serovar typhimurium</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>2005</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.4.2005-2011.2005</pub-id><pub-id pub-id-type="pmid">15784541</pub-id><pub-id pub-id-type="pmcid">PMC1087430</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Garmory, H. S. et al. Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live <italic toggle="yes">Salmonella enterica</italic> Serovar typhimurium. <italic toggle="yes">Infect. Immun.</italic><bold>73</bold>, 2005&#8211;2011 (2005).<pub-id pub-id-type="pmid">15784541</pub-id><pub-id pub-id-type="doi">10.1128/IAI.73.4.2005-2011.2005</pub-id><pub-id pub-id-type="pmcid">PMC1087430</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leckenby</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Enhanced vaccine antigen delivery by Salmonella with antibiotic free Operator Repressor Titration-based plasmid stabilisation compared to chromosomal integration</article-title><source>Microb. Pathog.</source><year>2009</year><volume>46</volume><fpage>201</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2009.01.001</pub-id><pub-id pub-id-type="pmid">19490834</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Leckenby, M. W. et al. Enhanced vaccine antigen delivery by Salmonella with antibiotic free Operator Repressor Titration-based plasmid stabilisation compared to chromosomal integration. <italic toggle="yes">Microb. Pathog.</italic><bold>46</bold>, 201&#8211;206 (2009).<pub-id pub-id-type="pmid">19490834</pub-id><pub-id pub-id-type="doi">10.1016/j.micpath.2009.01.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanapala</surname><given-names>S</given-names></name><etal/></person-group><article-title>Multiple antigens of <italic toggle="yes">Yersinia pestis</italic> delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague</article-title><source>Vaccine</source><year>2016</year><volume>5</volume><fpage>2410</fpage><lpage>2416</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.03.094</pub-id><pub-id pub-id-type="pmcid">PMC5484397</pub-id><pub-id pub-id-type="pmid">27060051</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Sanapala, S. et al. Multiple antigens of <italic toggle="yes">Yersinia pestis</italic> delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague. <italic toggle="yes">Vaccine</italic><bold>5</bold>, 2410&#8211;2416 (2016).<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.03.094</pub-id><pub-id pub-id-type="pmcid">PMC5484397</pub-id><pub-id pub-id-type="pmid">27060051</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sha</surname><given-names>J</given-names></name><etal/></person-group><article-title>The two murine lipoproteins of Salmonella enterica serovar Typhimurium contribute to the virulence of the organism</article-title><source>Infect. Immun.</source><year>2004</year><volume>72</volume><fpage>3987</fpage><lpage>4003</lpage><pub-id pub-id-type="doi">10.1128/IAI.72.7.3987-4003.2004</pub-id><pub-id pub-id-type="pmid">15213144</pub-id><pub-id pub-id-type="pmcid">PMC427434</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Sha, J. et al. The two murine lipoproteins of Salmonella enterica serovar Typhimurium contribute to the virulence of the organism. <italic toggle="yes">Infect. Immun.</italic><bold>72</bold>, 3987&#8211;4003 (2004).<pub-id pub-id-type="pmid">15213144</pub-id><pub-id pub-id-type="doi">10.1128/IAI.72.7.3987-4003.2004</pub-id><pub-id pub-id-type="pmcid">PMC427434</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qingmei</surname><given-names>J</given-names></name><etal/></person-group><article-title>Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>7009</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-24581-y</pub-id><pub-id pub-id-type="pmid">29725025</pub-id><pub-id pub-id-type="pmcid">PMC5934503</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Qingmei, J. et al. Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. <italic toggle="yes">Sci. Rep.</italic><bold>8</bold>, 7009 (2018).<pub-id pub-id-type="pmid">29725025</pub-id><pub-id pub-id-type="doi">10.1038/s41598-018-24581-y</pub-id><pub-id pub-id-type="pmcid">PMC5934503</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>P</given-names></name><etal/></person-group><article-title>A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e01926</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1128/mBio.01926-18</pub-id><pub-id pub-id-type="pmid">30327445</pub-id><pub-id pub-id-type="pmcid">PMC6191538</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Tao, P. et al. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague. <italic toggle="yes">mBio</italic><bold>9</bold>, e01926&#8211;18 (2018).<pub-id pub-id-type="pmid">30327445</pub-id><pub-id pub-id-type="doi">10.1128/mBio.01926-18</pub-id><pub-id pub-id-type="pmcid">PMC6191538</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilgore</surname><given-names>PB</given-names></name><etal/></person-group><article-title>A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform</article-title><source>Npj vaccines</source><year>2021</year><volume>6</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1038/s41541-020-00275-3</pub-id><pub-id pub-id-type="pmid">33514747</pub-id><pub-id pub-id-type="pmcid">PMC7846801</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Kilgore, P. B. et al. A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform. <italic toggle="yes">Npj vaccines</italic><bold>6</bold>, 21 (2021).<pub-id pub-id-type="pmid">33514747</pub-id><pub-id pub-id-type="doi">10.1038/s41541-020-00275-3</pub-id><pub-id pub-id-type="pmcid">PMC7846801</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sha</surname><given-names>J</given-names></name><etal/></person-group><article-title>A Replication-Defective Human type 5 adenovirus-based trivalent vaccine confers complete protection against plague in mice and nonhuman primates</article-title><source>Clin. Vaccin. Immunol.</source><year>2016</year><volume>23</volume><fpage>586</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1128/CVI.00150-16</pub-id><pub-id pub-id-type="pmcid">PMC4933772</pub-id><pub-id pub-id-type="pmid">27170642</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Sha, J. et al. A Replication-Defective Human type 5 adenovirus-based trivalent vaccine confers complete protection against plague in mice and nonhuman primates. <italic toggle="yes">Clin. Vaccin. Immunol.</italic><bold>23</bold>, 586&#8211;600 (2016).<pub-id pub-id-type="doi">10.1128/CVI.00150-16</pub-id><pub-id pub-id-type="pmcid">PMC4933772</pub-id><pub-id pub-id-type="pmid">27170642</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiuchiolo</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen</article-title><source>J. Infect. Dis.</source><year>2006</year><volume>194</volume><fpage>1249</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1086/507644</pub-id><pub-id pub-id-type="pmid">17041851</pub-id><pub-id pub-id-type="pmcid">PMC7109909</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Chiuchiolo, M. J. et al. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. <italic toggle="yes">J. Infect. Dis.</italic><bold>194</bold>, 1249&#8211;1257 (2006).<pub-id pub-id-type="pmid">17041851</pub-id><pub-id pub-id-type="doi">10.1086/507644</pub-id><pub-id pub-id-type="pmcid">PMC7109909</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyer</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Protective immunity against a lethal respiratory <italic toggle="yes">Yersinia pestis</italic> challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid</article-title><source>Hum. Gene Ther.</source><year>2010</year><volume>21</volume><fpage>891</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1089/hum.2009.148</pub-id><pub-id pub-id-type="pmid">20180652</pub-id><pub-id pub-id-type="pmcid">PMC2938358</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Boyer, J. L. et al. Protective immunity against a lethal respiratory <italic toggle="yes">Yersinia pestis</italic> challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid. <italic toggle="yes">Hum. Gene Ther.</italic><bold>21</bold>, 891&#8211;901 (2010).<pub-id pub-id-type="pmid">20180652</pub-id><pub-id pub-id-type="doi">10.1089/hum.2009.148</pub-id><pub-id pub-id-type="pmcid">PMC2938358</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Benefit-Risk Assessment of Vaccines by Technology Working Group BRAVATO, ex-V3SWG). Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations fora risk/benefit assessment</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>5248</fpage><lpage>5262</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.06.008</pub-id><pub-id pub-id-type="pmid">35715352</pub-id><pub-id pub-id-type="pmcid">PMC9194875</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Folegatti, P. M. et al. Benefit-Risk Assessment of Vaccines by Technology Working Group BRAVATO, ex-V3SWG). Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations fora risk/benefit assessment. <italic toggle="yes">Vaccine</italic><bold>40</bold>, 5248&#8211;5262 (2022).<pub-id pub-id-type="pmid">35715352</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.06.008</pub-id><pub-id pub-id-type="pmcid">PMC9194875</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><mixed-citation publication-type="other">WHO Landscape of plague vaccine candidates (2023).</mixed-citation></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albrecht</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>2012</year><volume>65</volume><fpage>505</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.2012.00974.x</pub-id><pub-id pub-id-type="pmid">22515653</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Albrecht, M. T. et al. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model. <italic toggle="yes">FEMS Immunol. Med. Microbiol.</italic><bold>65</bold>, 505&#8211;509 (2012).<pub-id pub-id-type="pmid">22515653</pub-id><pub-id pub-id-type="doi">10.1111/j.1574-695X.2012.00974.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><mixed-citation publication-type="other">Kon E. et al. A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium. <italic toggle="yes">Sci Adv</italic>. <bold>9</bold>10.1126/sciadv.adg1036 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adg1036</pub-id><pub-id pub-id-type="pmcid">PMC9995031</pub-id><pub-id pub-id-type="pmid">36888708</pub-id></mixed-citation></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shattock</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>A self-amplifying RNA vaccine provides protection in a murine model of bubonic plague</article-title><source>Front. Microbiol.</source><year>2023</year><volume>14</volume><fpage>1247041</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2023.1247041</pub-id><pub-id pub-id-type="pmid">38029221</pub-id><pub-id pub-id-type="pmcid">PMC10652872</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Shattock, R. J. et al. A self-amplifying RNA vaccine provides protection in a murine model of bubonic plague. <italic toggle="yes">Front. Microbiol.</italic><bold>14</bold>, 1247041 (2023).<pub-id pub-id-type="pmid">38029221</pub-id><pub-id pub-id-type="doi">10.3389/fmicb.2023.1247041</pub-id><pub-id pub-id-type="pmcid">PMC10652872</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><etal/></person-group><article-title>mRNA vaccines in disease prevention and treatment</article-title><source>Sig Transduct. Target Ther.</source><year>2023</year><volume>8</volume><fpage>365</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01579-1</pub-id><pub-id pub-id-type="pmcid">PMC10509165</pub-id><pub-id pub-id-type="pmid">37726283</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Zhang, G. et al. mRNA vaccines in disease prevention and treatment. <italic toggle="yes">Sig Transduct. Target Ther.</italic><bold>8</bold>, 365 (2023).<pub-id pub-id-type="doi">10.1038/s41392-023-01579-1</pub-id><pub-id pub-id-type="pmcid">PMC10509165</pub-id><pub-id pub-id-type="pmid">37726283</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>GH</given-names></name><name name-style="western"><surname>Lim</surname><given-names>SG</given-names></name></person-group><article-title>CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B&#174;) Update</article-title><source>Expert Rev. Vaccines.</source><year>2021</year><volume>20</volume><fpage>487</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1080/14760584.2021.1908133</pub-id><pub-id pub-id-type="pmid">33783302</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Lee, G. H. &amp; Lim, S. G. CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B&#174;) Update. <italic toggle="yes">Expert Rev. Vaccines.</italic><bold>20</bold>, 487&#8211;495 (2021).<pub-id pub-id-type="pmid">33783302</pub-id><pub-id pub-id-type="doi">10.1080/14760584.2021.1908133</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartley</surname><given-names>L</given-names></name><name name-style="western"><surname>Harold</surname><given-names>S</given-names></name><name name-style="western"><surname>Hawe</surname><given-names>E</given-names></name></person-group><article-title>The efficacy, safety and immunogenicity of plague vaccines: a systemic literature review</article-title><source>Curr. Res. Immunol.</source><year>2023</year><volume>4</volume><fpage>100072</fpage><pub-id pub-id-type="doi">10.1016/j.crimmu.2023.100072</pub-id><pub-id pub-id-type="pmid">37954941</pub-id><pub-id pub-id-type="pmcid">PMC10637890</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Hartley, L., Harold, S. &amp; Hawe, E. The efficacy, safety and immunogenicity of plague vaccines: a systemic literature review. <italic toggle="yes">Curr. Res. Immunol.</italic><bold>4</bold>, 100072 (2023).<pub-id pub-id-type="pmid">37954941</pub-id><pub-id pub-id-type="doi">10.1016/j.crimmu.2023.100072</pub-id><pub-id pub-id-type="pmcid">PMC10637890</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><mixed-citation publication-type="other">21CFR 601.90-95. Evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible <italic toggle="yes">Fed. Register</italic><bold>67</bold>, 37988-37998 (2002)<pub-id pub-id-type="pmid">12049094</pub-id></mixed-citation></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williamson</surname><given-names>ED</given-names></name><etal/></person-group><article-title>Recent advances in predictive models and correlates of protection in testing biodefence vaccines</article-title><source>Expert Rev. Vaccines</source><year>2010</year><volume>9</volume><fpage>527</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1586/erv.10.22</pub-id><pub-id pub-id-type="pmid">20450327</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Williamson, E. D. et al. Recent advances in predictive models and correlates of protection in testing biodefence vaccines. <italic toggle="yes">Expert Rev. Vaccines</italic><bold>9</bold>, 527&#8211;537 (2010).<pub-id pub-id-type="pmid">20450327</pub-id><pub-id pub-id-type="doi">10.1586/erv.10.22</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><mixed-citation publication-type="other">European Medicines Agency. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/ebola">https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/ebola</ext-link> (2024).</mixed-citation></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mogil</surname><given-names>JS</given-names></name><name name-style="western"><surname>Philip</surname><given-names>VM</given-names></name><name name-style="western"><surname>Tuttle</surname><given-names>AH</given-names></name><name name-style="western"><surname>Chesler</surname><given-names>EJ</given-names></name></person-group><article-title>Comparing phenotypic variation between inbred and outbred mice</article-title><source>Nat. Methods</source><year>2018</year><volume>15</volume><fpage>994</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1038/s41592-018-0224-7</pub-id><pub-id pub-id-type="pmid">30504873</pub-id><pub-id pub-id-type="pmcid">PMC6518396</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Mogil, J. S., Philip, V. M., Tuttle, A. H. &amp; Chesler, E. J. Comparing phenotypic variation between inbred and outbred mice. <italic toggle="yes">Nat. Methods</italic><bold>15</bold>, 994&#8211;996 (2018).<pub-id pub-id-type="pmid">30504873</pub-id><pub-id pub-id-type="doi">10.1038/s41592-018-0224-7</pub-id><pub-id pub-id-type="pmcid">PMC6518396</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majumder</surname><given-names>S</given-names></name><etal/></person-group><article-title>Protection Induced by Oral Vaccination with a Recombinant <italic toggle="yes">Yersinia pseudotuberculosis</italic> Delivering Yersinia pestis LcrV and F1 Antigens in Mice and Rats against Pneumonic Plague</article-title><source>Infect. Immu.</source><year>2022</year><volume>90</volume><fpage>e0016522</fpage><pub-id pub-id-type="doi">10.1128/iai.00165-22</pub-id><pub-id pub-id-type="pmcid">PMC9387218</pub-id><pub-id pub-id-type="pmid">35900096</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Majumder, S. et al. Protection Induced by Oral Vaccination with a Recombinant <italic toggle="yes">Yersinia pseudotuberculosis</italic> Delivering Yersinia pestis LcrV and F1 Antigens in Mice and Rats against Pneumonic Plague. <italic toggle="yes">Infect. Immu.</italic><bold>90</bold>, e0016522 (2022).<pub-id pub-id-type="doi">10.1128/iai.00165-22</pub-id><pub-id pub-id-type="pmcid">PMC9387218</pub-id><pub-id pub-id-type="pmid">35900096</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chichester</surname><given-names>JA</given-names></name><etal/></person-group><article-title>A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>3471</fpage><lpage>3474</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.01.050</pub-id><pub-id pub-id-type="pmid">19200825</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Chichester, J. A. et al. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague. <italic toggle="yes">Vaccine</italic><bold>27</bold>, 3471&#8211;3474 (2009).<pub-id pub-id-type="pmid">19200825</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.01.050</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smiley</surname><given-names>ST</given-names></name></person-group><article-title>Immune defense against pneumonic plague</article-title><source>Immunol. Rev.</source><year>2008</year><volume>22</volume><fpage>256</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00674.x</pub-id><pub-id pub-id-type="pmcid">PMC2804960</pub-id><pub-id pub-id-type="pmid">18837787</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Smiley, S. T. Immune defense against pneumonic plague. <italic toggle="yes">Immunol. Rev.</italic><bold>22</bold>, 256&#8211;271 (2008).<pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00674.x</pub-id><pub-id pub-id-type="pmcid">PMC2804960</pub-id><pub-id pub-id-type="pmid">18837787</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><mixed-citation publication-type="other">Williamson, E. D. &amp; Oyston, P. C. F. in Plotkins Vaccines (8th edition) (Ed. Orenstein, W. A., Offit, P. A., Edwards, K. M. &amp; Plotkin, S. A.) Chapter 46 (Elsevier, 2023).</mixed-citation></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parent</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary <italic toggle="yes">Yersinia pestis</italic> infection</article-title><source>Infect. Immun.</source><year>2006</year><volume>74</volume><fpage>3381</fpage><lpage>3386</lpage><pub-id pub-id-type="doi">10.1128/IAI.00185-06</pub-id><pub-id pub-id-type="pmid">16714568</pub-id><pub-id pub-id-type="pmcid">PMC1479272</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Parent, M. A. et al. Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary <italic toggle="yes">Yersinia pestis</italic> infection. <italic toggle="yes">Infect. Immun.</italic><bold>74</bold>, 3381&#8211;3386 (2006).<pub-id pub-id-type="pmid">16714568</pub-id><pub-id pub-id-type="doi">10.1128/IAI.00185-06</pub-id><pub-id pub-id-type="pmcid">PMC1479272</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elvin</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>ED</given-names></name></person-group><article-title>Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague</article-title><source>Micro. Pathog.</source><year>2004</year><volume>3</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2004.06.009</pub-id><pub-id pub-id-type="pmid">15458778</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Elvin, S. J. &amp; Williamson, E. D. Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague. <italic toggle="yes">Micro. Pathog.</italic><bold>3</bold>, 177&#8211;184 (2004).<pub-id pub-id-type="doi">10.1016/j.micpath.2004.06.009</pub-id><pub-id pub-id-type="pmid">15458778</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>Y</given-names></name><etal/></person-group><article-title>T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>6866</fpage><lpage>6873</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.059</pub-id><pub-id pub-id-type="pmid">21803090</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Levy, Y. et al. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague. <italic toggle="yes">Vaccine</italic><bold>29</bold>, 6866&#8211;6873 (2011).<pub-id pub-id-type="pmid">21803090</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamzabegovic</surname><given-names>F</given-names></name><etal/></person-group><article-title>Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures</article-title><source>NPJ Vaccines.</source><year>2020</year><volume>5</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1038/s41541-020-0156-y</pub-id><pub-id pub-id-type="pmid">31993217</pub-id><pub-id pub-id-type="pmcid">PMC6978331</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Hamzabegovic, F. et al. Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures. <italic toggle="yes">NPJ Vaccines.</italic><bold>5</bold>, 6 (2020).<pub-id pub-id-type="pmid">31993217</pub-id><pub-id pub-id-type="doi">10.1038/s41541-020-0156-y</pub-id><pub-id pub-id-type="pmcid">PMC6978331</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amemiya</surname><given-names>K</given-names></name><etal/></person-group><article-title>Binding sites of anti-LcrV monoclonal antibodies are more critical than the avidities and affinities for passive protection against <italic toggle="yes">Yersinia pestis</italic> infection in a bubonic plague model</article-title><source>Antibodies</source><year>2020</year><volume>9</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.3390/antib9030037</pub-id><pub-id pub-id-type="pmid">32756297</pub-id><pub-id pub-id-type="pmcid">PMC7551159</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Amemiya, K. et al. Binding sites of anti-LcrV monoclonal antibodies are more critical than the avidities and affinities for passive protection against <italic toggle="yes">Yersinia pestis</italic> infection in a bubonic plague model. <italic toggle="yes">Antibodies</italic><bold>9</bold>, 37 (2020).<pub-id pub-id-type="pmid">32756297</pub-id><pub-id pub-id-type="doi">10.3390/antib9030037</pub-id><pub-id pub-id-type="pmcid">PMC7551159</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrianaivoarimanana</surname><given-names>V</given-names></name><etal/></person-group><article-title>Potential human immunotherapeutics for plague</article-title><source>Immunother. Adv.</source><year>2021</year><volume>1</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/immadv/ltab020</pub-id><pub-id pub-id-type="pmcid">PMC9327098</pub-id><pub-id pub-id-type="pmid">35919741</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Andrianaivoarimanana, V. et al. Potential human immunotherapeutics for plague. <italic toggle="yes">Immunother. Adv.</italic><bold>1</bold>, 1&#8211;8 (2021).<pub-id pub-id-type="doi">10.1093/immadv/ltab020</pub-id><pub-id pub-id-type="pmcid">PMC9327098</pub-id><pub-id pub-id-type="pmid">35919741</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biryukov</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Functional assays to screen and select monoclonal antibodies that target <italic toggle="yes">Yersinia pestis</italic></article-title><source>Hum. Vaccines Immunotherapeutics</source><year>2023</year><volume>19</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1080/21645515.2023.2216085</pub-id><pub-id pub-id-type="pmcid">PMC10332183</pub-id><pub-id pub-id-type="pmid">37289480</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Biryukov, S. S. et al. Functional assays to screen and select monoclonal antibodies that target <italic toggle="yes">Yersinia pestis</italic>. <italic toggle="yes">Hum. Vaccines Immunotherapeutics</italic><bold>19</bold>, 2 (2023).<pub-id pub-id-type="doi">10.1080/21645515.2023.2216085</pub-id><pub-id pub-id-type="pmcid">PMC10332183</pub-id><pub-id pub-id-type="pmid">37289480</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><mixed-citation publication-type="other">International Standard Plague antiserum[Almond, Rajerison, Williamson, personal communication].</mixed-citation></ref><ref id="CR141"><label>141.</label><mixed-citation publication-type="other">Raveros X. Target Product Profiles Plague vaccines WHO <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cdn.who.int/media/docs/default-source/documents/r-d-blueprint-meetings/global-consultation-on-plague-vaccines/3_ximena-riveros_plague-tpp.pdf?sfvrsn=edbe8135_3">https://cdn.who.int/media/docs/default-source/documents/r-d-blueprint-meetings/global-consultation-on-plague-vaccines/3_ximena-riveros_plague-tpp.pdf?sfvrsn=edbe8135_3</ext-link> (2023).</mixed-citation></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rocke</surname><given-names>TE</given-names></name><etal/></person-group><article-title>Effects of climate change on plague exposure pathways and resulting disease dynamics</article-title><source>DoD. Final Rep.</source><year>2020</year><volume>16</volume><fpage>RC01</fpage><lpage>RC012</lpage></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Rocke, T. E. et al. Effects of climate change on plague exposure pathways and resulting disease dynamics. <italic toggle="yes">DoD. Final Rep.</italic><bold>16</bold>, RC01&#8211;RC012 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Climate-driven marmot-plague dynamics in Mongolia and China</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><fpage>11906</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-38966-1</pub-id><pub-id pub-id-type="pmid">37488160</pub-id><pub-id pub-id-type="pmcid">PMC10366125</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Xu, L. et al. Climate-driven marmot-plague dynamics in Mongolia and China. <italic toggle="yes">Sci. Rep.</italic><bold>13</bold>, 11906 (2023).<pub-id pub-id-type="pmid">37488160</pub-id><pub-id pub-id-type="doi">10.1038/s41598-023-38966-1</pub-id><pub-id pub-id-type="pmcid">PMC10366125</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leal Filho</surname><given-names>W</given-names></name><etal/></person-group><article-title>A Review of Concepts, Definitions, and Bibliometrics</article-title><source>Int J. Environ. Res. Public Health</source><year>2022</year><volume>19</volume><fpage>893</fpage><pub-id pub-id-type="doi">10.3390/ijerph19020893</pub-id><pub-id pub-id-type="pmid">35055715</pub-id><pub-id pub-id-type="pmcid">PMC8776135</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Leal Filho, W. et al. A Review of Concepts, Definitions, and Bibliometrics. <italic toggle="yes">Int J. Environ. Res. Public Health</italic><bold>19</bold>, 893 (2022).<pub-id pub-id-type="pmid">35055715</pub-id><pub-id pub-id-type="doi">10.3390/ijerph19020893</pub-id><pub-id pub-id-type="pmcid">PMC8776135</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartlow</surname><given-names>AW</given-names></name><etal/></person-group><article-title>Forecasting Zoonotic Infectious Disease Response to Climate Change: Mosquito Vectors and a Changing Environment</article-title><source>Vet. Sci.</source><year>2019</year><volume>6</volume><fpage>40</fpage><pub-id pub-id-type="pmid">31064099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vetsci6020040</pub-id><pub-id pub-id-type="pmcid">PMC6632117</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Bartlow, A. W. et al. Forecasting Zoonotic Infectious Disease Response to Climate Change: Mosquito Vectors and a Changing Environment. <italic toggle="yes">Vet. Sci.</italic><bold>6</bold>, 40 (2019).<pub-id pub-id-type="pmid">31064099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vetsci6020040</pub-id><pub-id pub-id-type="pmcid">PMC6632117</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><mixed-citation publication-type="other">WHO releases first data on global vaccine market since COVID-19 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news/item/09-11-2022-who-releases-first-data-on-global-vaccine-market-since-covid-19">https://www.who.int/news/item/09-11-2022-who-releases-first-data-on-global-vaccine-market-since-covid-19</ext-link>.</mixed-citation></ref><ref id="CR147"><label>147.</label><mixed-citation publication-type="other">WHO The Immunisation Agenda 2030 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789240062726">https://www.who.int/publications/i/item/9789240062726</ext-link>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>